1,385 results on '"Lorusso D."'
Search Results
2. Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data
- Author
-
Agostinelli V, Musacchio L, Camarda F, Salutari V, Carbone MV, Ghizzoni V, Nero C, Ricci C, Perri MT, Giudice E, Lardino S, Berardi R, Scambia G, and Lorusso D
- Subjects
cervical cancer ,gynecological cancer ,antibody–drug conjugate ,tissue factor. ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Veronica Agostinelli,1 Lucia Musacchio,2 Floriana Camarda,2 Vanda Salutari,2 Maria Vittoria Carbone,2 Viola Ghizzoni,2 Camilla Nero,2 Caterina Ricci,2 Maria Teresa Perri,2 Elena Giudice,3 Sara Lardino,3 Rossana Berardi,1 Giovanni Scambia,2,3 Domenica Lorusso2,3 1Oncologic Clinic, Università Politecnica delle Marche, Ancona, Italy; 2Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 3Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Vanda Salutari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, Roma, 00168, Italy, Tel +39-06-3015-3234, Email vanda.salutari@policlinicogemelli.itAbstract: Cervical cancer is the fourth most common type of cancer in women worldwide. It is associated with a high death rate, despite the fact that it is a nearly 100% preventable disease because of very effective primary and secondary preventive strategies. Advanced and recurrent disease is uncurable with a high relapse risk and the second-line therapies are limited with modest response rates and short durability. Investigating alternative mechanisms of action is crucial because of the high request for effective new therapies. Tisotumab vedotin (TV) is the first antibody-drug conjugated to target a cell surface-expressed tissue factor, and preliminary data in patients with metastatic and recurrent cervical cancer have been promising. In addition, the trials showed a favorable tolerability profile, with limited incidence of grade 3 or worse adverse events. According to the data of ENGOT-cx6/GOG-3023/innovaTV 204, the US Food and Drug Administration granted expedited approval of TV on September 20, 2021, for women with recurrent or metastatic cervical cancer. Actually, two other trials testing TV alone or in combination with other agents are ongoing. ENGOT-cx8/GOG-3024/innovaTV 205 is a Phase Ib/II trial of TV in combination with platinum or bevacizumab or pembrolizumab, in patients with recurrent or metastatic cervical cancer who have not received prior systemic therapy or who have progressed after no more than two prior systemic therapies. ENGOT-cx12/GOG-3057/InnovaTV 301 is a Phase 3 trial of TV vs investigator’s choice chemotherapy in patients with advanced or recurrent cervical cancer who had received no more than 2 prior chemotherapy lines. The outcomes of these two trials will potentially confirm and reinforce the use of TV as a new standard of care in advanced or recurrent cervical cancer.Keywords: cervical cancer, gynecological cancer, antibody–drug conjugate, tissue factor
- Published
- 2023
3. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
- Author
-
Ledermann, J.A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, D., Banerjee, S., Chiva, L., Cibula, D., Colombo, N., Croce, S., Eriksson, A.G., Falandry, C., Fischerova, D., Harter, P., Joly, F., Lazaro, C., Lok, C., Mahner, S., Marmé, F., Marth, C., McCluggage, W.G., McNeish, I.A., Morice, P., Nicum, S., Oaknin, A., Pérez-Fidalgo, J.A., Pignata, S., Ramirez, P.T., Ray-Coquard, I., Romero, I., Scambia, G., Sehouli, J., Shapira-Frommer, R., Sundar, S., Tan, D.S.P., Taskiran, C., van Driel, W.J., Vergote, I., Planchamp, F., Sessa, C., and Fagotti, A.
- Published
- 2024
- Full Text
- View/download PDF
4. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
- Author
-
Monk, B.J., Barretina-Ginesta, M.P., Pothuri, B., Vergote, I., Graybill, W., Mirza, M.R., McCormick, C.C., Lorusso, D., Moore, R.G., Freyer, G., O’Cearbhaill, R.E., Heitz, F., O’Malley, D.M., Redondo, A., Shahin, M.S., Vulsteke, C., Bradley, W.H., Haslund, C.A., Chase, D.M., Pisano, C., Holman, L.L., Pérez, M. J. Rubio, DiSilvestro, P., Gaba, L., Herzog, T.J., Bruchim, I., Compton, N., Shtessel, L., Malinowska, I.A., and González-Martín, A.
- Published
- 2024
- Full Text
- View/download PDF
5. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Author
-
González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R.E., Pothuri, B., Ray-Coquard, I., Tan, D.S.P., Bellet, E., Oaknin, A., and Ledermann, J.A.
- Published
- 2023
- Full Text
- View/download PDF
6. Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer
- Author
-
Vergote, I., Van Nieuwenhuysen, E., Casado, A., Laenen, A., Lorusso, D., Braicu, E.I., Guerra-Alia, E., Zola, P., Wimberger, P., Debruyne, P.R., Falcó, E., Ferrero, A., Muallem, M.Z., Kerger, J., García-Martinez, E., Pignata, S., Sehouli, J., Van Gorp, T., Gennigens, C., and Rubio, M.J.
- Published
- 2023
- Full Text
- View/download PDF
7. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer
- Author
-
Koppikar, S., Oaknin, A., Babu, K. Govind, Lorusso, D., Gupta, S., Wu, L.-Y., Rajabto, W., Harano, K., Hong, S.-H., Malik, R.A., Strebel, H., Aggarwal, I.M., Lai, C.-H., Dejthevaporn, T., Tangjitgamol, S., Cheng, W.F., Chay, W.Y., Benavides, D., Hashim, N.M., Moon, Y.W., Yunokawa, M., Anggraeni, T.D., Wei, W., Curigliano, G., Maheshwari, A., Mahantshetty, U., Sheshadri, S., Peters, S., Yoshino, T., and Pentheroudakis, G.
- Published
- 2023
- Full Text
- View/download PDF
8. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial
- Author
-
Tewari, K, Colombo, N, Monk, B, Dubot, C, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Salman, P, Yanez, E, Gumus, M, de Mendoza, M, Samouelian, V, Castonguay, V, Arkhipov, A, Tekin, C, Li, K, Toker, S, Keefe, S, Lorusso, D, Tewari K. S., Colombo N., Monk B. J., Dubot C., Caceres M. V., Hasegawa K., Shapira-Frommer R., Salman P., Yanez E., Gumus M., de Mendoza M. O. H., Samouelian V., Castonguay V., Arkhipov A., Tekin C., Li K., Toker S., Keefe S. M., Lorusso D., Tewari, K, Colombo, N, Monk, B, Dubot, C, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Salman, P, Yanez, E, Gumus, M, de Mendoza, M, Samouelian, V, Castonguay, V, Arkhipov, A, Tekin, C, Li, K, Toker, S, Keefe, S, Lorusso, D, Tewari K. S., Colombo N., Monk B. J., Dubot C., Caceres M. V., Hasegawa K., Shapira-Frommer R., Salman P., Yanez E., Gumus M., de Mendoza M. O. H., Samouelian V., Castonguay V., Arkhipov A., Tekin C., Li K., Toker S., Keefe S. M., and Lorusso D.
- Abstract
IMPORTANCE The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Treatment effects in patient subgroups of the study population are unknown. OBJECTIVE To assess efficacy outcomes in patient subgroups of KEYNOTE-826. DESIGN, SETTING, AND PARTICIPANTS Exploratory subgroup analyses were conducted in a global, phase 3, randomized, double-blind, placebo-controlled clinical trial. Participants included women with persistent, recurrent, or metastatic adenocarcinoma, adenosquamous carcinoma, or squamous cell carcinoma of the cervix that had not been treated with systemic chemotherapy and was not amenable to curative treatment. This subanalysis was conducted from November 20, 2018, to May 3, 2021. INTERVENTIONS Pembrolizumab, 200 mg, every 3 weeks or placebo for up to 35 cycles plus chemotherapy (paclitaxel, 175 mg/m2, plus cisplatin, 50 mg/m2, or carboplatin AUC 5 [area under the free carboplatin plasma concentration vs time curve]) with or without bevacizumab, 15 mg/kg. MAIN OUTCOMES AND MEASURES Overall survival (OS) and progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1 in subgroups defined by use of bevacizumab (yes or no), choice of platinum (carboplatin or cisplatin), prior chemoradiotherapy (CRT) exposure only (yes or no), and histologic type (squamous or nonsquamous) in patients with programmed cell death ligand 1-positive tumors (defined as a combined positive score [CPS] ≥1) and in the intention-to-treat population. RESULTS A total of 617 patients (median age, 51 years; range, 22-82 years) were enrolled in the trial. In the CPS greater than or equal to 1 population, hazard ratios (HRs) for OS favored the pembrolizumab group in all subgroups: with bevacizumab (HR, 0.62; 95% CI, 0.45-0.8
- Published
- 2024
9. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
- Author
-
Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alia, E.M., Bogner, G., Yoshida, H., Lefeuvre-Plesse, C., Buderath, P., Mosconi, A.M., Lortholary, A., Burges, A., Medioni, J., El-Balat, A., Rodrigues, M., Park-Simon, T.-W., Dubot, C., Denschlag, D., You, B., Pujade-Lauraine, E., and Harter, P.
- Published
- 2023
- Full Text
- View/download PDF
10. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
- Author
-
Capoluongo, E.D., Pellegrino, B., Arenare, L., Califano, D., Scambia, G., Beltrame, L., Serra, V., Scaglione, G.L., Spina, A., Cecere, S.C., De Cecio, R., Normanno, N., Colombo, N., Lorusso, D., Russo, D., Nardelli, C., D’Incalci, M., Llop-Guevara, A., Pisano, C., Baldassarre, G., Mezzanzanica, D., Artioli, G., Setaro, M., Tasca, G., Roma, C., Campanini, N., Cinieri, S., Sergi, A., Musolino, A., Perrone, F., Chiodini, P., Marchini, S., and Pignata, S.
- Published
- 2022
- Full Text
- View/download PDF
11. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Author
-
Oaknin, A., Bosse, T.J., Creutzberg, C.L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M.R., Ledermann, J.A., and Colombo, N.
- Published
- 2022
- Full Text
- View/download PDF
12. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
- Author
-
Musacchio, L., Cicala, C.M., Camarda, F., Ghizzoni, V., Giudice, E., Carbone, M.V., Ricci, C., Perri, M.T., Tronconi, F., Gentile, M., Salutari, V., Scambia, G., and Lorusso, D.
- Published
- 2022
- Full Text
- View/download PDF
13. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
- Author
-
Ochsenreither, S., Fiedler, W.M., Conte, G.D., Macchini, M., Matos, I., Habel, B., Ahrens-Fath, I., Raspagliesi, F., Lorusso, D., Keilholz, U., Rolling, C., Kebenko, M., Klinghammer, K.F., Saavedra, O., Baumeister, H., Zurlo, A., and Garralda, E.
- Published
- 2022
- Full Text
- View/download PDF
14. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
- Author
-
Vergote, I., Ausems, M., Brasiuniene, B., Brenton, J., Büttner, R., Colombo, N., González-Martín, A., Harter, P., Lambrechts, D., Lorusso, D., Madry, R., Mirza, M.R., Pujol, P., Ray-Coquard, I., Abreu, M., Balboni, S., Banerjee, S., Barberis, M., Barretina Ginesta, M.P., Baurain, J.-F., Bignami, M., Bjorge, L., Blecharz, P., Bruchim, I., Capilna, M., Cerana, N., Cicchetti, A., Collins, D., Concin, N., D’Incalci, M., Davidson, B., de la Motte Rouge, T., De Iaco, P., Demirkiran, F., Denys, H., Doerk, T., Dorum, A., Ferrero, A., Fidalgo, A.P., Genuardi, M., Gladieff, L., Glasspool, R., Grimm, C., Gultekin, M., Hahnen, E., Hasenburg, A., Hegmane, A., Heinzelmann, V., Hogdall, E., Janavicius, R., Jarmalaite, S., Kalachand, R., Kaneva, R., Kilickap, S., Kocian, R., Kolencik, D., Kristeleit, R., Kryzhanivska, A., Leary, A., Lemley, B., Ligtenberg, M., López-Guerrero, J.A., Lord, C.J., Avall-Lundqvist, E., Maenpaa, J., Mahner, S., Marmé, F., Marth, C., McNeish, I., Merkelbach-Bruse, S., Mourits, M., Normanno, N., Oaknin, A., Ojamaa, K., Papdimitriou, C., Penault-Llorca, F., Perrone, A.M., Pignata, S., Pikarsky, E., Rouleau, E., Rubio, M., Sapino, A., Schmalfeldt, B., Sehouli, J., Shapira, R., Steffensen, K.D., Sukhin, V., Syrios, J., Szallasi, Z., Taskiran, C., Terzic, M., Tischkowitz, M., Toth, I., Van de Vijver, K., Vardar, M.A., Wasag, B., Wimberger, P., Witteveen, E., Brenton, J.D., and Ausems, M.G.E.M.
- Published
- 2022
- Full Text
- View/download PDF
15. 102P A retrospective description of actionable mutations incidence within a comprehensive cancer genome profiling programme: Is less still more?
- Author
-
Camarda, F., primary, Nero, C., additional, Giacomini, F., additional, Duranti, S., additional, Bria, E., additional, Salvatore, L., additional, Iacovelli, R., additional, Marino, I., additional, Minucci, A., additional, Giacò, L., additional, Pasciuto, T., additional, Giannarelli, D., additional, Fagotti, A., additional, Fanfani, F., additional, Zannoni, G.F., additional, Lorusso, D., additional, Tortora, G., additional, Normanno, N., additional, and Scambia, G., additional
- Published
- 2024
- Full Text
- View/download PDF
16. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
- Author
-
Moore, K.N., Oza, A.M., Colombo, N., Oaknin, A., Scambia, G., Lorusso, D., Konecny, G.E., Banerjee, S., Murphy, C.G., Tanyi, J.L., Hirte, H., Konner, J.A., Lim, P.C., Prasad-Hayes, M., Monk, B.J., Pautier, P., Wang, J., Berkenblit, A., Vergote, I., and Birrer, M.J.
- Published
- 2021
- Full Text
- View/download PDF
17. Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy
- Author
-
Berardi, R., Torniai, M., Cona, M.S., Cecere, F.L., Chiari, R., Guarneri, V., La Verde, N., Locati, L., Lorusso, D., Martinelli, E., Giannarelli, D., and Garassino, M.C.
- Published
- 2021
- Full Text
- View/download PDF
18. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
- Author
-
Pignata, S, Lorusso, D, Joly, F, Gallo, C, Colombo, N, Sessa, C, Bamias, A, Salutari, V, Selle, F, Frezzini, S, De Giorgi, U, Pautier, P, Bologna, A, Orditura, M, Dubot, C, Gadducci, A, Mammoliti, S, Ray-Coquard, I, Zafarana, E, Breda, E, Favier, L, Ardizzoia, A, Cinieri, S, Largillier, R, Sambataro, D, Guardiola, E, Lauria, R, Pisano, C, Raspagliesi, F, Scambia, G, Daniele, G, Perrone, F, Pignata, Sandro, Lorusso, Domenica, Joly, Florence, Gallo, Ciro, Colombo, Nicoletta, Sessa, Cristiana, Bamias, Aristotelis, Salutari, Vanda, Selle, Frédèric, Frezzini, Simona, De Giorgi, Ugo, Pautier, Patricia, Bologna, Alessandra, Orditura, Michele, Dubot, Coraline, Gadducci, Angiolo, Mammoliti, Serafina, Ray-Coquard, Isabelle, Zafarana, Elena, Breda, Enrico, Favier, Laure, Ardizzoia, Antonio, Cinieri, Saverio, Largillier, Rémy, Sambataro, Daniela, Guardiola, Emmanuel, Lauria, Rossella, Pisano, Carmela, Raspagliesi, Francesco, Scambia, Giovanni, Daniele, Gennaro, and Perrone, Francesco
- Published
- 2021
- Full Text
- View/download PDF
19. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- Author
-
Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, Ledermann, Jonathan A, investigators, ARIEL3, Buck, M, Dean, A, Friedlander, ML, Goh, JC, Harnett, P, Kichenadasse, G, Scott, CL, Denys, H, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, AM, Plante, M, Provencher, D, Weberpals, JI, Welch, S, Floquet, A, Gladieff, L, Joly, F, Leary, A, Lortholary, A, Lotz, J, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Pignata, S, Sabbatini, RF, Scambia, G, Tamberi, S, Zamagni, C, Fong, PC, O'Donnell, A, Gancedo, M Amenedo, Herraez, A Casado, Garcia-Donas, J, Guerra, EM, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, SN, Clamp, A, Drew, Y, Gabra, HG, Jackson, D, Ledermann, JA, McNeish, IA, Parkinson, C, and Powell, M
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Orphan Drug ,Clinical Research ,Cancer ,Genetics ,Clinical Trials and Supportive Activities ,Ovarian Cancer ,Rare Diseases ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,6.2 Cellular and gene therapies ,Aged ,Disease-Free Survival ,Double-Blind Method ,Female ,Follow-Up Studies ,Humans ,Indoles ,Internationality ,Maintenance Chemotherapy ,Middle Aged ,Molecular Targeted Therapy ,Neoplasm Recurrence ,Local ,Ovarian Neoplasms ,Poly(ADP-ribose) Polymerase Inhibitors ,Risk Assessment ,Survival Rate ,Treatment Outcome ,ARIEL3 investigators ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundRucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.MethodsIn this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0-1, and had adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or fewer before starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-generated sequence (block size of six, stratified by homologous recombination repair gene mutation status, progression-free interval after the penultimate platinum-based regimen, and best response to the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary outcome was investigator-assessed progression-free survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), patients with homologous recombination deficiencies (BRCA mutant or BRCA wild-type and high loss of heterozygosity), and the intention-to-treat population, assessed at screening and every 12 weeks thereafter. This trial is registered with ClinicalTrials.gov, number NCT01968213; enrolment is complete.FindingsBetween April 7, 2014, and July 19, 2016, we randomly allocated 564 patients: 375 (66%) to rucaparib and 189 (34%) to placebo. Median progression-free survival in patients with a BRCA-mutant carcinoma was 16·6 months (95% CI 13·4-22·9; 130 [35%] patients) in the rucaparib group versus 5·4 months (3·4-6·7; 66 [35%] patients) in the placebo group (hazard ratio 0·23 [95% CI 0·16-0·34]; p
- Published
- 2017
20. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
- Author
-
Colombo, N, Lorusso, D, Monk, B, Slomovitz, B, Hasegawa, K, Nogueira-Rodrigues, A, Zale, M, Okpara, C, Barresi, G, Mckenzie, J, Makker, V, Colombo, Nicoletta, Lorusso, Domenica, Monk, Bradley J, Slomovitz, Brian, Hasegawa, Kosei, Nogueira-Rodrigues, Angélica, Zale, Melissa, Okpara, Chinyere E, Barresi, Gianmaria, McKenzie, Jodi, Makker, Vicky, Colombo, N, Lorusso, D, Monk, B, Slomovitz, B, Hasegawa, K, Nogueira-Rodrigues, A, Zale, M, Okpara, C, Barresi, G, Mckenzie, J, Makker, V, Colombo, Nicoletta, Lorusso, Domenica, Monk, Bradley J, Slomovitz, Brian, Hasegawa, Kosei, Nogueira-Rodrigues, Angélica, Zale, Melissa, Okpara, Chinyere E, Barresi, Gianmaria, McKenzie, Jodi, and Makker, Vicky
- Abstract
Background: Lenvatinib plus pembrolizumab significantly improved efficacy compared with chemotherapy in patients with advanced endometrial cancer (aEC) regardless of microsatellite instability status or histologic subtype, who had disease progression following prior platinum-based therapy, in Study-309/KEYNOTE-775. The safety profile of the combination was generally consistent with that of each monotherapy drug and of the combination in patients with endometrial cancer and other solid tumors. Given the medical complexity of patients with aEC, this paper aims to characterize key adverse reactions (ARs) of the combination treatment and review management strategies, providing a guide for AR management to maximize anticancer benefits and minimize treatment discontinuation. Materials and Methods: In Study-309/KEYNOTE-775, patients received lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously every 3 weeks) or chemotherapy (doxorubicin or paclitaxel). The incidence and median time to the first onset of ARs, dose modifications, and concomitant medications are described. Key ARs characterized include hypothyroidism, hypertension, fatigue, diarrhea, musculoskeletal disorders, nausea, decreased appetite, vomiting, stomatitis, weight decreased, proteinuria, and palmar-plantar erythrodysesthesia syndrome. Results: As expected, the most common any-grade key ARs included: hypothyroidism, hypertension, fatigue, diarrhea, and musculoskeletal disorders. Grades 3-4 key ARs with incidence ≥10% included: hypertension, fatigue, and weight decreased. Key ARs first occurred within approximately 3 months of treatment initiation. AR management strategies consistent with the prescribing information and the study protocol are discussed. Conclusion: Successful AR management strategies for lenvatinib plus pembrolizumab include education of the patient and entire treatment team, preventative measures and close monitoring, and judicious use of dose modifications and conco
- Published
- 2024
21. Reply to P.-H. Luo et al
- Author
-
Monk, B, Colombo, N, Tewari, K, Tekin, C, Keefe, S, Lorusso, D, Monk, Bradley J, Colombo, Nicoletta, Tewari, Krishnansu S, Tekin, Cumhur, Keefe, Stephen M, Lorusso, Domenica, Monk, B, Colombo, N, Tewari, K, Tekin, C, Keefe, S, Lorusso, D, Monk, Bradley J, Colombo, Nicoletta, Tewari, Krishnansu S, Tekin, Cumhur, Keefe, Stephen M, and Lorusso, Domenica
- Published
- 2024
22. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
- Author
-
Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, Randall, Leslie M, Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M
- Abstract
Background: The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone. Methods: In this investigator-initiated, randomised, open-label, phase 3 trial, patients from 92 sites in Europe, Japan, and the USA with metastatic (stage IVB), persistent, or recurrent cervical cancer that was measurable, previously untreated, and not amenable to curative surgery or radiation were randomly assigned 1:1 to receive standard therapy (cisplatin 50 mg/m2 or carboplatin area under the curve of 5, paclitaxel 175 mg/m2, and bevacizumab 15 mg/kg, all on day 1 of every 3-week cycle) with or without atezolizumab 1200 mg. Treatment was continued until disease progression, unacceptable toxicity, patient withdrawal, or death. Stratification factors were previous concomitant chemoradiation (yes vs no), histology (squamous cell carcinoma vs adenocarcinoma including adenosquamous carcinoma), and platinum backbone (cisplatin vs carboplatin). Dual primary endpoints were investigator-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumours version 1.1 and overall survival analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03556839, and is ongoing. Findings: Between Oct 8, 2018, and Aug 20, 2021, 410 of 519 patients assessed for eligibility were enrolled. Median progression-free survival was 13·7 months (95% CI 12·3–16·6) with atezolizumab and 10·4 months (9·7–11·7) with standard therapy (hazard ratio [HR]=0·62 [95% CI 0·49–0·78]; p<0·0001); at the interim overall survival analysis, median overall survival was 32·1 months (95% CI 25·3–36·8) versus 22·8 months (20·3–28·0), respectively (HR 0·68 [95% CI 0·52–0·88]; p=0·0046). Grade 3 or worse adverse events occurred in 79% of patient
- Published
- 2024
23. New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere
- Author
-
Bruchim, I., Capasso, Ilaria, Polonsky, A., Meisel, S., Salutari, V., Werner, H., Lorusso, D., Scambia, Giovanni, Fanfani, Francesco, Capasso I., Scambia G. (ORCID:0000-0003-2758-1063), Fanfani F. (ORCID:0000-0003-1991-7284), Bruchim, I., Capasso, Ilaria, Polonsky, A., Meisel, S., Salutari, V., Werner, H., Lorusso, D., Scambia, Giovanni, Fanfani, Francesco, Capasso I., Scambia G. (ORCID:0000-0003-2758-1063), and Fanfani F. (ORCID:0000-0003-1991-7284)
- Abstract
Introduction: Endometrial cancer (EC) is the only gynecologic malignancy showing increasing trends in incidence and mortality. While standard treatment has been effective primarily for early-stage EC, precision medicine with tailored therapy has revolutionized the management of this disease. Genome sequencing analyses have identified four sub-types of EC. Treatments for primary and metastatic disease can now be tailored more accurately to achieve better oncologic results. Areas covered: This review provides an overview of the most relevant and updated evidence in the literature regarding EC molecular analysis and its role in risk classification, prognostication, and guidance for tailored and target therapies in early and advanced/metastatic stages. In addition, it provides updated information on optimal surgical management based on molecular classification and highlights key advances and future strategies. Expert opinion: EC molecular analysis yields the potential of tailoring adjuvant treatment by escalating or deescalating therapy, as shown for POLE-mutated and p53-mutated tumors. Moreover, the expression of specific molecular signatures offers the possibility to employ novel target therapies, such as immune-checkpoint inhibitors that have demonstrated a significant benefit on prognosis. New treatment guidelines are still being established, and ongoing studies are exploring the potential prognostic role of further sub-stratifications of the four molecular classes and treatment options.
- Published
- 2024
24. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
- Author
-
Ledermann, J. A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, Domenica, Banerjee, S., Chiva, L., Cibula, D., Colombo, N., Croce, S., Eriksson, A. G., Falandry, C., Fischerova, D., Harter, P., Joly, F., Lazaro, C., Lok, C., Mahner, S., Marmé, F., Marth, C., Mccluggage, W. G., Mcneish, I. A., Morice, P., Nicum, S., Oaknin, A., Pérez-Fidalgo, J. A., Pignata, S., Ramirez, P. T., Ray-Coquard, I., Romero, I., Scambia, Giovanni, Sehouli, J., Shapira-Frommer, R., Sundar, S., Tan, D. S. P., Taskiran, C., van Driel, W. J., Vergote, I., Planchamp, F., Sessa, C., Fagotti, Anna, Lorusso, D., Scambia, G. (ORCID:0000-0003-2758-1063), Fagotti, A. (ORCID:0000-0001-5579-335X), Ledermann, J. A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, Domenica, Banerjee, S., Chiva, L., Cibula, D., Colombo, N., Croce, S., Eriksson, A. G., Falandry, C., Fischerova, D., Harter, P., Joly, F., Lazaro, C., Lok, C., Mahner, S., Marmé, F., Marth, C., Mccluggage, W. G., Mcneish, I. A., Morice, P., Nicum, S., Oaknin, A., Pérez-Fidalgo, J. A., Pignata, S., Ramirez, P. T., Ray-Coquard, I., Romero, I., Scambia, Giovanni, Sehouli, J., Shapira-Frommer, R., Sundar, S., Tan, D. S. P., Taskiran, C., van Driel, W. J., Vergote, I., Planchamp, F., Sessa, C., Fagotti, Anna, Lorusso, D., Scambia, G. (ORCID:0000-0003-2758-1063), and Fagotti, A. (ORCID:0000-0001-5579-335X)
- Abstract
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.
- Published
- 2024
25. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
- Author
-
Mirza, Mansoor R., Benigno, B., Dørum, A., Mahner, S., Bessette, P., Barceló, I. Bover, Berton-Rigaud, D., Ledermann, J.A., Rimel, B.J., Herrstedt, J., Lau, S., du Bois, A., Herráez, A. Casado, Kalbacher, E., Buscema, J., Lorusso, D., Vergote, I., Levy, T., Wang, P., de Jong, F.A., Gupta, D., and Matulonis, U.A.
- Published
- 2020
- Full Text
- View/download PDF
26. Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study
- Author
-
Lorusso, D., Marchetti, C., Conte, C., Giudice, E., Bolomini, G., Vertechy, L., Ceni, V., Ditto, A., Ferrandina, G., Raspagliesi, F., Scambia, G., and Fagotti, A.
- Published
- 2020
- Full Text
- View/download PDF
27. VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
- Author
-
Oaknin, A., primary, Gladieff, L., additional, Martinez-Garcia, J., additional, Villacampa, G., additional, Takekuma, M., additional, De Giorgi, U.F.F., additional, Lindemann, K., additional, Woelber, L., additional, Colombo, N., additional, Duska, L.R., additional, Leary, A., additional, Godoy Ortiz, A., additional, Nishio, S., additional, Angelergues, A., additional, Rubio Perez, M.J., additional, Fariñas Madrid, L., additional, Yamaguchi, S., additional, Lorusso, D., additional, D'Hondt, V., additional, and Randall, L., additional
- Published
- 2023
- Full Text
- View/download PDF
28. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial
- Author
-
Lorusso, D., Ferrandina, G., Colombo, N., Pignata, S., Pietragalla, A., Sonetto, C., Pisano, C., Lapresa, M.T., Savarese, A., Tagliaferri, P., Lombardi, D., Cinieri, S., Breda, E., Sabatucci, I., Sabbatini, R., Conte, C., Cecere, S.C., Maltese, G., and Scambia, G.
- Published
- 2019
- Full Text
- View/download PDF
29. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice
- Author
-
Lorusso, D, Colombo, N, Herraez, A, Santin, A, Colomba, E, Miller, D, Fujiwara, K, Pignata, S, Baron-Hay, S, Ray-Coquard, I, Shapira-Frommer, R, Kim, Y, Mccormack, M, Massaad, R, Nguyen, A, Zhao, Q, Mckenzie, J, Prabhu, V, Makker, V, Lorusso D., Colombo N., Herraez A. C., Santin A. D., Colomba E., Miller D. S., Fujiwara K., Pignata S., Baron-Hay S. E., Ray-Coquard I. L., Shapira-Frommer R., Kim Y. M., McCormack M., Massaad R., Nguyen A. M., Zhao Q., McKenzie J., Prabhu V. S., Makker V., Lorusso, D, Colombo, N, Herraez, A, Santin, A, Colomba, E, Miller, D, Fujiwara, K, Pignata, S, Baron-Hay, S, Ray-Coquard, I, Shapira-Frommer, R, Kim, Y, Mccormack, M, Massaad, R, Nguyen, A, Zhao, Q, Mckenzie, J, Prabhu, V, Makker, V, Lorusso D., Colombo N., Herraez A. C., Santin A. D., Colomba E., Miller D. S., Fujiwara K., Pignata S., Baron-Hay S. E., Ray-Coquard I. L., Shapira-Frommer R., Kim Y. M., McCormack M., Massaad R., Nguyen A. M., Zhao Q., McKenzie J., Prabhu V. S., and Makker V.
- Abstract
Purpose: Lenvatinib and pembrolizumab (LEN+PEMBRO) demonstrated clinically meaningful and statistically significant improvements in efficacy versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer (aEC) in the phase 3 Study 309/KEYNOTE-775. Health-related quality-of-life (HRQoL) is reported. Patients and Methods: Patients were randomly assigned to receive LEN+PEMBRO (n = 411; LEN 20 mg/day; PEMBRO 200 mg Q3W) or TPC (n = 416; doxorubicin 60 mg/m2 Q3W or paclitaxel 80 mg/m2 [weekly, 3 weeks on/1 week off]). Impact of treatment on HRQoL assessed by the global health status/quality of life (GHS/QoL) score of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) was a secondary objective; other scales of the Quality-of-Life Questionnaire (QLQ-C30), EORTC QLQ-Endometrial, 24 questions (EORTC QLQ-EN24), and EuroQoL 5 dimensions, 5 levels (EQ-5D-5L) were exploratory objectives. HRQoL was assessed on day 1 of each cycle. Completion/compliance, change from baseline, time to first and definitive deterioration were assessed. No multiplicity adjustments were applied for HRQoL endpoints. Results: The latest timepoint at which the predefined rates of completion (≥60%) and compliance (≥80%) were met was week 12. HRQoL at week 12 between treatment groups was generally similar. Time to first deterioration symptom scales favoured LEN+PEMBRO for QLQ-C30 dyspnoea, and QLQ-EN24 for poor body image, tingling/numbness, and hair loss; and TPC was favoured for QLQ-C30 pain, appetite loss, and diarrhoea, and QLQ-EN24 muscular pain. While the QLQ-C30 physical functional scale favoured TPC, other functional scales were generally similar between arms. Time to definitive deterioration favoured LEN+PEMBRO on most scales. Conclusion: HRQoL data from Study 309/KEYNOTE-775, with previously published efficacy and safety results, indicate that LEN+PEMBRO has an overall favourable benefit/risk profile versus TPC fo
- Published
- 2023
30. Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer
- Author
-
Paracchini, L, Mannarino, L, Romualdi, C, Zadro, R, Beltrame, L, Nerini, I, Zola, P, Laudani, M, Pagano, E, Giordano, L, Fruscio, R, Landoni, F, Franceschi, S, Dalessandro, M, Canzonieri, V, Bocciolone, L, Lorusso, D, Bosetti, C, Raspagliesi, F, Garassino, I, D'Incalci, M, Marchini, S, Grassi, T, Bianchi, T, Cursano, G, Mangili, G, Scambia, G, Marchetti, C, Boldorini, R, De Rosa, G, Ferrero, A, Feyles, E, Goia, M, Manini, C, Orlassino, R, Surico, D, Volante, M, Greggi, S, Jaconi, M, Bella, C, Vitobello, D, di Loreto, C, Pizzolitto, S, Zanconati, F, Ciccone, G, Armaroli, P, Larato, C, Rizzolo, R, Paracchini L., Mannarino L., Romualdi C., Zadro R., Beltrame L., Nerini I. F., Zola P., Laudani M. E., Pagano E., Giordano L., Fruscio R., Landoni F., Franceschi S., Dalessandro M. L., Canzonieri V., Bocciolone L., Lorusso D., Bosetti C., Raspagliesi F., Garassino I. M. G., D'Incalci M., Marchini S., Grassi T., Bianchi T., Cursano G., Mangili G., Scambia G., Marchetti C., Boldorini R., De Rosa G., Ferrero A., Feyles E., Goia M., Manini C., Orlassino R., Surico D., Volante M., Greggi S., Jaconi M., Bella C. D., Vitobello D., di Loreto C., Pizzolitto S., Zanconati F., Ciccone G., Armaroli P., Larato C., Rizzolo R., Paracchini, L, Mannarino, L, Romualdi, C, Zadro, R, Beltrame, L, Nerini, I, Zola, P, Laudani, M, Pagano, E, Giordano, L, Fruscio, R, Landoni, F, Franceschi, S, Dalessandro, M, Canzonieri, V, Bocciolone, L, Lorusso, D, Bosetti, C, Raspagliesi, F, Garassino, I, D'Incalci, M, Marchini, S, Grassi, T, Bianchi, T, Cursano, G, Mangili, G, Scambia, G, Marchetti, C, Boldorini, R, De Rosa, G, Ferrero, A, Feyles, E, Goia, M, Manini, C, Orlassino, R, Surico, D, Volante, M, Greggi, S, Jaconi, M, Bella, C, Vitobello, D, di Loreto, C, Pizzolitto, S, Zanconati, F, Ciccone, G, Armaroli, P, Larato, C, Rizzolo, R, Paracchini L., Mannarino L., Romualdi C., Zadro R., Beltrame L., Nerini I. F., Zola P., Laudani M. E., Pagano E., Giordano L., Fruscio R., Landoni F., Franceschi S., Dalessandro M. L., Canzonieri V., Bocciolone L., Lorusso D., Bosetti C., Raspagliesi F., Garassino I. M. G., D'Incalci M., Marchini S., Grassi T., Bianchi T., Cursano G., Mangili G., Scambia G., Marchetti C., Boldorini R., De Rosa G., Ferrero A., Feyles E., Goia M., Manini C., Orlassino R., Surico D., Volante M., Greggi S., Jaconi M., Bella C. D., Vitobello D., di Loreto C., Pizzolitto S., Zanconati F., Ciccone G., Armaroli P., Larato C., and Rizzolo R.
- Abstract
Late diagnosis and the lack of screening methods for early detection define high-grade serous ovarian cancer (HGSOC) as the gynecological malignancy with the highest mortality rate. In the work presented here, we investigated a retrospective and multicentric cohort of 250 archival Papanicolaou (Pap) test smears collected during routine gynecological screening. Samples were taken at different time points (from 1 month to 13.5 years before diagnosis) from 113 presymptomatic women who were subsequently diagnosed with HGSOC (pre-HGSOC) and from 77 healthy women. Genome instability was detected through low-pass whole-genome sequencing of DNA derived from Pap test samples in terms of copy number profile abnormality (CPA). CPA values of DNA extracted from Pap test samples from pre-HGSOC women were substantially higher than those in samples from healthy women. Consistently with the longitudinal analysis of clonal pathogenic TP53 mutations, this assay could detect HGSOC presence up to 9 years before diagnosis. This finding confirms the continual shedding of tumor cells from fimbriae toward the endocervical canal, suggesting a new path for the early diagnosis of HGSOC. We integrated the CPA score into the EVA (early ovarian cancer) test, the sensitivity of which was 75% (95% CI, 64.97 to 85.79), the specificity 96% (95% CI, 88.35 to 100.00), and the accuracy 81%. This proof-of-principle study indicates that the early diagnosis of HGSOC is feasible through the analysis of genomic alterations in DNA from endocervical smears.
- Published
- 2023
31. Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study
- Author
-
Bergamini, A., Cormio, G., Ferrandina, G., Lorusso, D., Giorda, G., Scarfone, G., Bocciolone, L., Raspagliesi, F., Tateo, S., Cassani, C., Savarese, A., Breda, E., De Giorgi, U., Mascilini, F., Candiani, M., Kardhashi, A., Biglia, N., Perrone, A.M., Pignata, S., and Mangili, G.
- Published
- 2019
- Full Text
- View/download PDF
32. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
- Author
-
Baert, T., Banerjee, S., Belaroussi, I., Blecharz, P., Bruchim, I., Cibula, D., Colombo, N., Concin, N., Davidson, B., Dashora, A., Devouassoux-Shisheboran, M., du Bois, A., Ferrero, A., Glasspool, R., González-Martin, A., Heinzelmann-Schwarz, V., Joly, F., Kim, J.W., Kridelka, F., Ledermann, J., Lorusso, D., Mahner, S., McCluggage, W.G., McNeish, I., Mikami, M., Mirza, M.R., Morice, P., Nicum, S., Olbrecht, S., O’Donnell, D.M., Pautier, P., Planchamp, F., Pignata, S., Querleu, D., Ray-Coquard, I., Rodolakis, A., Sehouli, J., Selcukbiricik, F., Sessa, C., Singh, N., Tan, D.S.P., Timmerman, D., Tognon, G., van der Velden, J., Vergote, I., Witteveen, P.O., and Zeimet, A.G.
- Published
- 2019
- Full Text
- View/download PDF
33. Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
- Author
-
Hackl, Monika, Van Eycken, Elizabeth, Henau, Kris, Dimitrova, Nadya, Sekerija, Mario, Dušek, Ladislav, Mägi, Margit, Malila, Nea, Leinonen, Maarit, Velten, Michel, Troussard, Xavier, Bouvier, Veronique, Guizard, Anne-Valérie, Bouvier, Anne-Marie, Arveux, Patrick, Maynadié, Marc, Woronoff, Anne-Sophie, Robaszkiewicz, Michel, Baldi, Isabelle, Monnereau, Alain, Tretarre, Brigitte, Colonna, Marc, Molinié, Florence, Bara, Simona, Schvartz, Claire, Lapôtre-Ledoux, Bénédicte, Grosclaude, Pascale, Stabenow, Roland, Luttmann, Sabine, Nennecke, Alice, Engel, Jutta, Schubert-Fritschle, Gabriele, Heidrich, Jan, Holleczek, Bernd, Jónasson, Jón Gunnlaugur, Clough-Gorr, Kerri, Comber, Harry, Mazzoleni, Guido, Giacomin, Adriano, Sardo, Antonella Sutera, Barchielli, Alessandro, Serraino, Diego, De Angelis, Roberta, Mallone, Sandra, Tavilla, Andrea, Pierannunzio, Daniela, Rossi, Silvia, Santaquilani, Mariano, Knijn, Arnold, Pannozzo, Fabio, Gennaro, Valerio, Benfatto, Lucia, Ricci, Paolo, Autelitano, Mariangela, Spagnoli, Gianbattista, Fusco, Mario, Usala, Mario, Vitale, Francesco, Michiara, Maria, Tumino, Rosario, Mangone, Lucia, Falcini, Fabio, Ferretti, Stefano, Filiberti, Rosa Angela, Marani, Enza, Iannelli, Arturo, Sensi, Flavio, Piffer, Silvano, Gentilini, Maria, Madeddu, Anselmo, Ziino, Antonio, Maspero, Sergio, Candela, Pina, Stracci, Fabrizio, Tagliabue, Giovanna, Rugge, Massimo, Trama, Annalisa, Gatta, Gemma, Botta, Laura, Capocaccia, Riccardo, Pildava, Santa, Smailyte, Giedre, Calleja, Neville, Johannesen, Tom Børge, Rachtan, Jadwiga, Góźdź, Stanisław, Błaszczyk, Jerzy, Kępska, Kamila, de Lacerda, Gonçalo Forjaz, José Bento, Maria, Miranda, Ana, Safaei Diba, Chakameh, Almar, Enrique, Larrañaga, Nerea, de Munain, Arantza Lopez, Torrella-Ramos, Ana, Díaz García, José María, Marcos-Gragera, Rafael, Josè Sanchez, Maria, Navarro, Carmen, Salmeron, Diego, Moreno-Iribas, Conchi, Galceran, Jaume, Carulla, Marià, Mousavi, Mohsen, Bouchardy, Christine, Ess, Silvia M., Bordoni, Andrea, Konzelmann, Isabelle, Rashbass, Jem, Gavin, Anna, Brewster, David H., Huws, Dyfed Wyn, Visser, Otto, Bielska-Lasota, Magdalena, Primic-Zakelj, Maja, Kunkler, Ian, Benhamou, Ellen, Ray-Coquard, I., Trama, AnnaLisa, Seckl, M.J., Fotopoulou, C., Pautier, P., Pignata, S., Kristensen, G., Mangili, G., Falconer, H., Massuger, L., Sehouli, J., Pujade-Lauraine, E., Lorusso, D., Amant, F., Rokkones, E., Vergote, I., and Ledermann, J.A.
- Published
- 2019
- Full Text
- View/download PDF
34. 10P An adapted CGP-based model to interpret POLE mutations in endometrial cancer
- Author
-
Trozzi, R., primary, Ottaviani, M., additional, Nero, C., additional, Duranti, S., additional, Camarda, F., additional, Marino, I., additional, Giacò, L., additional, De Marco, L., additional, Preziosi, A., additional, Minucci, A., additional, de Bonis, M., additional, Perrucci, A., additional, Onori, M.E., additional, Maneri, G., additional, Sillano, F., additional, Lorusso, D., additional, Fanfani, F., additional, Pasciuto, T., additional, Mozzetta, I., additional, and Scambia, G., additional
- Published
- 2023
- Full Text
- View/download PDF
35. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Author
-
Ray-Coquard, I., Morice, P., Lorusso, D., Prat, J., Oaknin, A., Pautier, P., and Colombo, N.
- Published
- 2018
- Full Text
- View/download PDF
36. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer
- Author
-
Piccirillo, M.C., Scambia, G., Bologna, A., Signoriello, S., Vergote, I., Baumann, K., Lorusso, D., Murgia, V., Sorio, R., Ferrandina, G., Sacco, C., Cormio, G., Breda, E., Cinieri, S., Natale, D., Mangili, G., Pisano, C., Cecere, S.C., Di Napoli, M., Salutari, V., Raspagliesi, F., Arenare, L., Bergamini, A., Bryce, J., Daniele, G., Gallo, C., Pignata, S., and Perrone, F.
- Published
- 2018
- Full Text
- View/download PDF
37. An international assessment of the adoption of enhanced recovery after surgery (ERAS®) principles across colorectal units in 2019–2020
- Author
-
Pinkney T., Taylor H., Tong C., Schmitz N. -D., Morton D. G., Pinkney T. D., Bhangu A., Blackwell S., Dardanov D., Dulskas A., Gallo G., Glasbey J., Keatley J., Knowles C., Li Y. E., McCourt V., Minaya-Bravo A., Neary P., Nepogodiev D., Pata F., Pellino G., Sivrikoz E., van Ramshorst G., Zmora O., Perry R., Magill E. L., Abdalkoddus M., Abelevich A., Abraham S., Abraham-Nordling M., Adamina M., Agalar C., Agresta F., Ahallat M., Ahmad N., Aiupov R., Akca O., Aleksic A., Aleotti F., Alias D., Alonso J., Alonso Goncalves S., Alonso Martin J., Alonso Poza A., Alonso-Hernandez N., Alos Company R., Al-Saeedi M., Alvarez-Laso C., Alvarez-Gallego M., Amanatidis T., Americano M., Amorim E., Anandan L., Anania G., Ancans G., Andreev P., Andrejevic P., Antonacci N., Anwer M., Aonzo P., Arencibia B., Argeny S., Arieli H., Arnold S., Ashraf M., Aslam M., Atanasov B., Atif M., Atladottir J., Avital S., Awny S., Aytac B., Azahr N., Aznar-Puig S., Bailey S., Balalis D., Baldi C., Baldonedo R., Balducci G., Balestra F., Balestri R., Balfour A., Baloyiannis I., Banky B., Baral J., Baranyai Z., Barbashinov N., Bargallo J., Barisic G., Barugola G., Batashki I., Battersby N., Belev N., Belli A., Beltran de Heredia J., Bemelman W., Benavides Buleje J., Benckert A., Bernal-Sprekelsen J., Bertocchi E., Beuran M., Bhan C., Bianco F., Bilali S., Bilali V., Bintintan V., Birindelli A., Birsan T., Blanco Antona F., Blas J., Blasco-Segura T., Blom R., Bocchetti T., Boerma E., Bogdan M., Boland M., Bomans B., Borda N., Bowen M., Bradulskis S., Branagan G., Brankovic B., Brenna M., Brewer H., Broadhurst J., Bronder C., Brouwer R., Buccianti P., Buchs N., Buchwald P., Bugatti A., Bui A., Burcos T., Buskens C., Bustamante C., Caceres N., Cagigas Fernandez C., Calero-Lillo A., Camps I., Canda A., Caravaca-Garcia I., Carballo F., Carcoforo P., Carlander J., Carlos S., Caro A., Carpelan A., Carrasco Prats M., Carrillo Lopez M., Carvello M., Casal E., Casoni Pattacini G., Castellvi Valls J., Castillo Diego J., Cavallesco G., Cavenaile V., Cayetano L., Ceccotti A., Cervera-Aldama J., Chabok A., Chafai N., Chandrasinghe P., Chandratreya N., Chaudhri S., Chaudhry Z., Cherdancev D., Chernov A., Chevallay M., Chirletti P., Chouillard E., Chouliaras C., Chowdri N., Cillo M., Cini C., Ciubotaru C., Ciuce C., Claeys D., Cocorullo G., Codina-Cazador A., Colak E., Coletta D., Colombo F., Copaescu C., Corte Real J., Corver M., Cosic J., Costa S., Costa Pereira J., Costa Pereira C., Costa-Navarro D., Cotte E., Cracco N., Cristian D., Cuadrado M., Cuk V., Cunha M., Cunha J., Curinga R., Curletti G., Curtis N., Dabic D., Dainius E., d'Alessandro A., Daniels I., Darvin V., Dauser B., David G., Davidova O., Davies E., de Andres Asenjo B., De franciscis S., de Graaf E., De la Portilla F., De Luca E., De Nisco C., De Toma G., Defoort B., Den Boer F., Di Candido F., Di Saverio S., Diaz Pavon J., Dieguez Fernandez B., Diez-Alonso M., Dimitrijevic I., Dindelegan G., Djuric M., Domingos H., Doornebosch P., Dos Santos M., Drami I., Dudarovaska H., Dusek T., Dzhumabaev H., Eden Y., Egenvall M., Eismiontas V., El Sorogy M., Elgeidie A., Elhemaly M., El-Hussuna A., Ellul S., Elmore U., ElNakeeb A., Elrefai M., Emile S., Enrriquez-Navascues J., Epstein J., Escartin J., Escola D., Escuder J., Espin E., Espina B., Estefania D., Etienne J., Fabbri S., Falato A., Fares R., Farina P., Farkasova M., Farres R., Fasolini F., Fatayer T., Febles G., Feliu F., Feo C., Feoktistov D., Fernandez F., Fernandez Isart M., Fernando J., Ferreira G., Ferrer R., Ferreras Garcia C., Ferri M., Figueiredo N., Finotti E., Fitzgerald J., Flateh Backe I., Flor-Lorente B., Forero-Torres A., Foschi D., Francart D., Francois Y., Frasson M., Freil-Lanter C., Frois Borges M., Fuzun M., Gala T., Galleano R., Galvez P., Galvez Saldana A., Gamundi Cuesta M., Garcia Cabrera A., Garcia Egea J., Garcia Olmo D., Garcia-Gonzalez J., Garcia-Granero A., Garcia-Granero E., Garcia-Septiem J., Gardea A., Garipov M., Gefen R., Geraghty A., Gerkis S., Germanos S., Ghaffari S., Ghilles E., Gianotti L., Gil Santos M., Gilsanz Martin C., Gingert C., Gklavas A., Glehen O., Golda T., Gomez N., Gomez R., Gomez Ruiz M., Gonzalez Santin V., Graham B., Grainger J., Grama F., Gregoir T., Gregori M., Grolich T., Grosek J., Guadalajara H., Guckenheimer S., Guevara J., Gulotta G., Gupta S., Gurevich N., Gurjar S., Haapaniemi S., Hahnloser D., Hamad Y., Hamid M., Hanly A., Harris G., Harsanyi L., Hartig N., Hawkin P., Henriques P., Herbst F., Hermann N., Hernandez Garcia M., Hoch J., Hrora A., Huhtinen H., Iarumov N., Ilkanich A., Insua C., Ioannidis P., Iqbal M., Iqbal A., Isik A., Ismaiel M., Ivlev D., Jadhav V., Jareno S., Jehaes C., Jimenez V., Jimenez-Toscano M., Jimenez-Miramon J., Jimenez-Rodriguez R., Jonsson T., Jotautas V., Julia D., Juloski J., Jung B., Kala Z., Kalayci M., Kara Y., Karachun A., Karagul S., Karvonen J., Katorkin S., Katsoulis I., Katsounis D., Kaubrys M., Kaul N., Kefalou E., Keijzers M., Kelly M., Kenic M., Kennelly R., Khan J., Khan M., Kho H., Kinas V., Knight J., Kocian P., Koeter T., Kokobelyan A., Konsten J., Koolen L., Kosir J., Kostic I., Krdzic I., Kreisler Moreno E., Krivokapic Z., Krstev P., Krsul D., Kumarasinghe N., La Torre F., Labarga F., Ladra M., Lage Laredo A., Lahodzich N., Lai C., Lakkis Z., Lal R., Lamas S., Lang T., Latkauskas T., Lawes D., Lazar G., Lebedev K., Lebedeva M., Lefevre J., Lekic Vitlov V., Lemma M., Leo C., Leon C., Leventoglu S., Levy B., Li L., Licari L., Lizdenis P., Loftas P., Longhi M., Longstaff L., Lopez Dominguez J., Lopez-Lara M., Lora P., Lorenzon L., Lorusso D., Lozev I., Lozoya Trujillo R., Lukic D., Lunins R., Luzan R., Luzzi A., Maderuelo V., Madsboll T., Mahotin D., Majbar M., Makhmudov A., Malik K., Maly O., Mamaloudis I., Mamedli Z., Manatakis D., Mandi D., Mangell P., Marharint T., Mariani N., Maric B., Marimuthu K., Marinello F., Marino F., Markiewicz S., Markovic V., Marom G., Maroni N., Maroulis I., Marsanic P., Marsman H., Martens M., Marti M., Martinek L., Martinez S., Martinez D., Martinez Manzano A., Martins R., Maslyankov S., McArdle K., McDermott F., Mege D., Mehraj A., Mehta A., Mendrila D., Menendez P., Mercantini P., Metwally I., Mikalauskas S., Millan M., Mingoli A., Mirshekar-Syahkal B., Moggia E., Mohan S., Moller P., Mompart Garcia S., Monami B., Moniz Pereira P., Montroni I., Morel P., Moshev B., Mostovoy E., Mothe S., Mukhtar H., Muller P., Munch S., Munoz Camarena J., Munoz-Collado S., Muratore A., Muscara F., Muysoms F., Myrelid P., N. Lah N., Nail S., Narayanan A., Nastos K., Negoi I., Nesbakken A., Nestler G., Nestorovic M., Nesytykh A., Newton K., Ng Y., Ngu J., Nguyen B., Nijs Y., Nikberg M., Nimmersgern T., Nogues E., Norcic G., Nutautiene V., Nygren J., O'Brien J., Ochogavia Segui A., O'Kelly J., Oliveira-Cunha M., Omar W., Omar G., Onishchenko S., Onody P., Opocher E., Orhalmi J., Oshowo A., Otero J., Ozgen U., Pace K., Padin H., Papaconstantinou I., Papadopoulos A., Papadopoulos G., Papandrea M., Paral J., Parc Y., Paredes J., Parmar M., Parra Banos P., Parray F., Pascual Damieta M., Pascual Miguelanez I., Passot G., Pastor C., Paszt A., Patel P., Paterson H., Patron Uriburu J., Paulos A., Pavlov V., Pcolkins A., Pecic V., Pena Ros E., Penkov R., Pera Roman M., Perunicic V., Pery R., Petrovic D., Pezzolla F., Photi E., Pikarsky A., Piramanayagam B., Pisani Ceretti A., Planellas P., Platt E., Pletinckx P., Podda M., Poskus T., Poskus E., Pozdnyakov A., Pravosudov I., Previsic A., Prieto D., Prochazka V., Prodan A., Proud D., Psaila J., Psaras G., Pulighe F., Pullig F., Qureshi M., Rachadell J., Radovanovic Z., Radovanovic D., Raguan B., Rahman M., Raiss M., Ramirez Faraco M., Ramos J., Ramos-Prada J., Rantala A., Rao M., Rasulov A., Ratnatunga K., Raymond T., Refky B., Reggiani L., Regusci L., Reyes Diaz M., Richardson J., Richiteanu G., Rios A., Ris F., Rodriguez Garcia P., Roffi N., Romairone E., Romano G., Romero I., Romero de Diego A., Romero-Simo M., Roque C., Rosati R., Rossi B., Rossi E., Rossini R., Ruano A., Rubbini M., Rubio-Perez I., Ruffo G., Ruiz H., Ruiz Carmona M., Ryska O., Sabia D., Sacchi M., Sacco R., Sakr A., Saladzinskas Z., Salamone G., Salomon M., Salvans Ruiz S., Sammarco G., Sampietro G., Samsonov D., Samsonyuk V., Sanchez J., Sanchez Romero A., Sanchez-Guillen L., Santak G., Santamaria-Olabarrieta M., Santos J., Saraceno F., Saralegui Y., Sarici I., Savino G., Scabini S., Schafli J., Schiltz B., Schofield A., Schon M., Scurtu R., Segalini E., Segelman J., Segura-Sampedro J., Seicean R., Sekulic A., Selniahina L., Seretis F., Serrano Paz P., Shaikh I., Shalaby M., Shams N., Sharma A., Sharma G., Shukla A., Shussman N., Shweejawee Z., Sielezneff I., Sigurdsson H., Sileri P., Silva M., Simcikas D., Simoes J., Simonka Z., Singh B., Sivins A., Skroubis G., Skull A., Slavchev M., Slavin M., Smart N., Smart C., Smart P., Smedh K., Smolarek S., Sokmen S., Sokolov M., Solana Bueno A., Solar L., Sorrentino L., Sotona O., Spacca D., Spinelli A., Stanojevic G., Stearns A., Stefan S., Stift A., Stijns J., Stoyanov V., Straarup D., Strupas K., Stubbs B., Subocius A., Sudlow A., Suero C., Sungurtekin U., Svagzdys S., Syk I., Tamelis A., Tamhane R., Tamini N., Tamosiunas A., Tanis P., Tarasov N., Tate S., Tennakoon A., Teo N., Terzi C., Tezas S., Thabet W., Tham J., Thavanesan N., Theodosopoulos T., Thomas W., Tiret E., Tiselius C., Todorov G., Tomazic A., Tomulescu V., Torkington J., Totis M., Trostchansky I., Truan N., Tulchinsky H., Tutino R., Tzivanakis A., Tzovaras G., Ugolini G., Unger L., Upanishad I., Urbani L., Uth Ovesen A., Vaizey C., Vallribera F., Valsdottir E., Valverde I., Valverde-Sintas J., Van Belle K., Van Cleven S., van Hagen P., van Loon Y., van Ruler O., Van Wijck K., Varabei A., Varcada M., Varpe P., Vartic M., Velchuru V., Vencius J., Venskutonis D., Vercher D., Vermaas M., Vertruyen M., Verza L., Vescio G., Vezakis A., Vieira P., Vignali A., Vigorita V., Vila Tura M., Vinson-Bonnet B., Viso Pons L., Voloshin S., Voronin Y., Vukusic L., Wang X., Wang J., Wani R., Warusavitarne J., Wasserberg N., Weerts J., Weiss D., Weizman A., Westerduin E., Wheat J., White I., Wik T., Wilson J., Winter D., Wolthuis A., Wong M., Yahia S., Yamamoto T., Yanishev A., Yao C., Yildiz A., Yuksel O., Zain Z., Zakaria A., Zakaria Z., Zampitis N., Zarand A., Zarco-Pleguezuelos A., Zattoni D., Zelic M., Zeromskas P., Zhuravlev A., Zimmerman D., Zuhdy M., Zukanovic G., Surgery, CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, Graduate School, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Amsterdam Neuroscience - Neuroinfection & -inflammation, APH - Methodology, APH - Personalized Medicine, Pinkney, T, Taylor, H, Tong, C, Schmitz, N, Morton, D, Bhangu, A, Blackwell, S, Dardanov, D, Dulskas, A, Gallo, G, Glasbey, J, Keatley, J, Knowles, C, Li, Y, Mccourt, V, Minaya-Bravo, A, Neary, P, Nepogodiev, D, Pata, F, Pellino, G, Sivrikoz, E, van Ramshorst, G, Zmora, O, Perry, R, Magill, E, Abdalkoddus, M, Abelevich, A, Abraham, S, Abraham-Nordling, M, Adamina, M, Agalar, C, Agresta, F, Ahallat, M, Ahmad, N, Aiupov, R, Akca, O, Aleksic, A, Aleotti, F, Alias, D, Alonso, J, Alonso Goncalves, S, Alonso Martin, J, Alonso Poza, A, Alonso-Hernandez, N, Alos Company, R, Al-Saeedi, M, Alvarez-Laso, C, Alvarez-Gallego, M, Amanatidis, T, Americano, M, Amorim, E, Anandan, L, Anania, G, Ancans, G, Andreev, P, Andrejevic, P, Antonacci, N, Anwer, M, Aonzo, P, Arencibia, B, Argeny, S, Arieli, H, Arnold, S, Ashraf, M, Aslam, M, Atanasov, B, Atif, M, Atladottir, J, Avital, S, Awny, S, Aytac, B, Azahr, N, Aznar-Puig, S, Bailey, S, Balalis, D, Baldi, C, Baldonedo, R, Balducci, G, Balestra, F, Balestri, R, Balfour, A, Baloyiannis, I, Banky, B, Baral, J, Baranyai, Z, Barbashinov, N, Bargallo, J, Barisic, G, Barugola, G, Batashki, I, Battersby, N, Belev, N, Belli, A, Beltran de Heredia, J, Bemelman, W, Benavides Buleje, J, Benckert, A, Bernal-Sprekelsen, J, Bertocchi, E, Beuran, M, Bhan, C, Bianco, F, Bilali, S, Bilali, V, Bintintan, V, Birindelli, A, Birsan, T, Blanco Antona, F, Blas, J, Blasco-Segura, T, Blom, R, Bocchetti, T, Boerma, E, Bogdan, M, Boland, M, Bomans, B, Borda, N, Bowen, M, Bradulskis, S, Branagan, G, Brankovic, B, Brenna, M, Brewer, H, Broadhurst, J, Bronder, C, Brouwer, R, Buccianti, P, Buchs, N, Buchwald, P, Bugatti, A, Bui, A, Burcos, T, Buskens, C, Bustamante, C, Caceres, N, Cagigas Fernandez, C, Calero-Lillo, A, Camps, I, Canda, A, Caravaca-Garcia, I, Carballo, F, Carcoforo, P, Carlander, J, Carlos, S, Caro, A, Carpelan, A, Carrasco Prats, M, Carrillo Lopez, M, Carvello, M, Casal, E, Casoni Pattacini, G, Castellvi Valls, J, Castillo Diego, J, Cavallesco, G, Cavenaile, V, Cayetano, L, Ceccotti, A, Cervera-Aldama, J, Chabok, A, Chafai, N, Chandrasinghe, P, Chandratreya, N, Chaudhri, S, Chaudhry, Z, Cherdancev, D, Chernov, A, Chevallay, M, Chirletti, P, Chouillard, E, Chouliaras, C, Chowdri, N, Cillo, M, Cini, C, Ciubotaru, C, Ciuce, C, Claeys, D, Cocorullo, G, Codina-Cazador, A, Colak, E, Coletta, D, Colombo, F, Copaescu, C, Corte Real, J, Corver, M, Cosic, J, Costa, S, Costa Pereira, J, Costa Pereira, C, Costa-Navarro, D, Cotte, E, Cracco, N, Cristian, D, Cuadrado, M, Cuk, V, Cunha, M, Cunha, J, Curinga, R, Curletti, G, Curtis, N, Dabic, D, Dainius, E, D'Alessandro, A, Daniels, I, Darvin, V, Dauser, B, David, G, Davidova, O, Davies, E, de Andres Asenjo, B, De franciscis, S, de Graaf, E, De la Portilla, F, De Luca, E, De Nisco, C, De Toma, G, Defoort, B, Den Boer, F, Di Candido, F, Di Saverio, S, Diaz Pavon, J, Dieguez Fernandez, B, Diez-Alonso, M, Dimitrijevic, I, Dindelegan, G, Djuric, M, Domingos, H, Doornebosch, P, Dos Santos, M, Drami, I, Dudarovaska, H, Dusek, T, Dzhumabaev, H, Eden, Y, Egenvall, M, Eismiontas, V, El Sorogy, M, Elgeidie, A, Elhemaly, M, El-Hussuna, A, Ellul, S, Elmore, U, Elnakeeb, A, Elrefai, M, Emile, S, Enrriquez-Navascues, J, Epstein, J, Escartin, J, Escola, D, Escuder, J, Espin, E, Espina, B, Estefania, D, Etienne, J, Fabbri, S, Falato, A, Fares, R, Farina, P, Farkasova, M, Farres, R, Fasolini, F, Fatayer, T, Febles, G, Feliu, F, Feo, C, Feoktistov, D, Fernandez, F, Fernandez Isart, M, Fernando, J, Ferreira, G, Ferrer, R, Ferreras Garcia, C, Ferri, M, Figueiredo, N, Finotti, E, Fitzgerald, J, Flateh Backe, I, Flor-Lorente, B, Forero-Torres, A, Foschi, D, Francart, D, Francois, Y, Frasson, M, Freil-Lanter, C, Frois Borges, M, Fuzun, M, Gala, T, Galleano, R, Galvez, P, Galvez Saldana, A, Gamundi Cuesta, M, Garcia Cabrera, A, Garcia Egea, J, Garcia Olmo, D, Garcia-Gonzalez, J, Garcia-Granero, A, Garcia-Granero, E, Garcia-Septiem, J, Gardea, A, Garipov, M, Gefen, R, Geraghty, A, Gerkis, S, Germanos, S, Ghaffari, S, Ghilles, E, Gianotti, L, Gil Santos, M, Gilsanz Martin, C, Gingert, C, Gklavas, A, Glehen, O, Golda, T, Gomez, N, Gomez, R, Gomez Ruiz, M, Gonzalez Santin, V, Graham, B, Grainger, J, Grama, F, Gregoir, T, Gregori, M, Grolich, T, Grosek, J, Guadalajara, H, Guckenheimer, S, Guevara, J, Gulotta, G, Gupta, S, Gurevich, N, Gurjar, S, Haapaniemi, S, Hahnloser, D, Hamad, Y, Hamid, M, Hanly, A, Harris, G, Harsanyi, L, Hartig, N, Hawkin, P, Henriques, P, Herbst, F, Hermann, N, Hernandez Garcia, M, Hoch, J, Hrora, A, Huhtinen, H, Iarumov, N, Ilkanich, A, Insua, C, Ioannidis, P, Iqbal, M, Iqbal, A, Isik, A, Ismaiel, M, Ivlev, D, Jadhav, V, Jareno, S, Jehaes, C, Jimenez, V, Jimenez-Toscano, M, Jimenez-Miramon, J, Jimenez-Rodriguez, R, Jonsson, T, Jotautas, V, Julia, D, Juloski, J, Jung, B, Kala, Z, Kalayci, M, Kara, Y, Karachun, A, Karagul, S, Karvonen, J, Katorkin, S, Katsoulis, I, Katsounis, D, Kaubrys, M, Kaul, N, Kefalou, E, Keijzers, M, Kelly, M, Kenic, M, Kennelly, R, Khan, J, Khan, M, Kho, H, Kinas, V, Knight, J, Kocian, P, Koeter, T, Kokobelyan, A, Konsten, J, Koolen, L, Kosir, J, Kostic, I, Krdzic, I, Kreisler Moreno, E, Krivokapic, Z, Krstev, P, Krsul, D, Kumarasinghe, N, La Torre, F, Labarga, F, Ladra, M, Lage Laredo, A, Lahodzich, N, Lai, C, Lakkis, Z, Lal, R, Lamas, S, Lang, T, Latkauskas, T, Lawes, D, Lazar, G, Lebedev, K, Lebedeva, M, Lefevre, J, Lekic Vitlov, V, Lemma, M, Leo, C, Leon, C, Leventoglu, S, Levy, B, Li, L, Licari, L, Lizdenis, P, Loftas, P, Longhi, M, Longstaff, L, Lopez Dominguez, J, Lopez-Lara, M, Lora, P, Lorenzon, L, Lorusso, D, Lozev, I, Lozoya Trujillo, R, Lukic, D, Lunins, R, Luzan, R, Luzzi, A, Maderuelo, V, Madsboll, T, Mahotin, D, Majbar, M, Makhmudov, A, Malik, K, Maly, O, Mamaloudis, I, Mamedli, Z, Manatakis, D, Mandi, D, Mangell, P, Marharint, T, Mariani, N, Maric, B, Marimuthu, K, Marinello, F, Marino, F, Markiewicz, S, Markovic, V, Marom, G, Maroni, N, Maroulis, I, Marsanic, P, Marsman, H, Martens, M, Marti, M, Martinek, L, Martinez, S, Martinez, D, Martinez Manzano, A, Martins, R, Maslyankov, S, Mcardle, K, Mcdermott, F, Mege, D, Mehraj, A, Mehta, A, Mendrila, D, Menendez, P, Mercantini, P, Metwally, I, Mikalauskas, S, Millan, M, Mingoli, A, Mirshekar-Syahkal, B, Moggia, E, Mohan, S, Moller, P, Mompart Garcia, S, Monami, B, Moniz Pereira, P, Montroni, I, Morel, P, Moshev, B, Mostovoy, E, Mothe, S, Mukhtar, H, Muller, P, Munch, S, Munoz Camarena, J, Munoz-Collado, S, Muratore, A, Muscara, F, Muysoms, F, Myrelid, P, N. Lah, N, Nail, S, Narayanan, A, Nastos, K, Negoi, I, Nesbakken, A, Nestler, G, Nestorovic, M, Nesytykh, A, Newton, K, Ng, Y, Ngu, J, Nguyen, B, Nijs, Y, Nikberg, M, Nimmersgern, T, Nogues, E, Norcic, G, Nutautiene, V, Nygren, J, O'Brien, J, Ochogavia Segui, A, O'Kelly, J, Oliveira-Cunha, M, Omar, W, Omar, G, Onishchenko, S, Onody, P, Opocher, E, Orhalmi, J, Oshowo, A, Otero, J, Ozgen, U, Pace, K, Padin, H, Papaconstantinou, I, Papadopoulos, A, Papadopoulos, G, Papandrea, M, Paral, J, Parc, Y, Paredes, J, Parmar, M, Parra Banos, P, Parray, F, Pascual Damieta, M, Pascual Miguelanez, I, Passot, G, Pastor, C, Paszt, A, Patel, P, Paterson, H, Patron Uriburu, J, Paulos, A, Pavlov, V, Pcolkins, A, Pecic, V, Pena Ros, E, Penkov, R, Pera Roman, M, Perunicic, V, Pery, R, Petrovic, D, Pezzolla, F, Photi, E, Pikarsky, A, Piramanayagam, B, Pisani Ceretti, A, Planellas, P, Platt, E, Pletinckx, P, Podda, M, Poskus, T, Poskus, E, Pozdnyakov, A, Pravosudov, I, Previsic, A, Prieto, D, Prochazka, V, Prodan, A, Proud, D, Psaila, J, Psaras, G, Pulighe, F, Pullig, F, Qureshi, M, Rachadell, J, Radovanovic, Z, Radovanovic, D, Raguan, B, Rahman, M, Raiss, M, Ramirez Faraco, M, Ramos, J, Ramos-Prada, J, Rantala, A, Rao, M, Rasulov, A, Ratnatunga, K, Raymond, T, Refky, B, Reggiani, L, Regusci, L, Reyes Diaz, M, Richardson, J, Richiteanu, G, Rios, A, Ris, F, Rodriguez Garcia, P, Roffi, N, Romairone, E, Romano, G, Romero, I, Romero de Diego, A, Romero-Simo, M, Roque, C, Rosati, R, Rossi, B, Rossi, E, Rossini, R, Ruano, A, Rubbini, M, Rubio-Perez, I, Ruffo, G, Ruiz, H, Ruiz Carmona, M, Ryska, O, Sabia, D, Sacchi, M, Sacco, R, Sakr, A, Saladzinskas, Z, Salamone, G, Salomon, M, Salvans Ruiz, S, Sammarco, G, Sampietro, G, Samsonov, D, Samsonyuk, V, Sanchez, J, Sanchez Romero, A, Sanchez-Guillen, L, Santak, G, Santamaria-Olabarrieta, M, Santos, J, Saraceno, F, Saralegui, Y, Sarici, I, Savino, G, Scabini, S, Schafli, J, Schiltz, B, Schofield, A, Schon, M, Scurtu, R, Segalini, E, Segelman, J, Segura-Sampedro, J, Seicean, R, Sekulic, A, Selniahina, L, Seretis, F, Serrano Paz, P, Shaikh, I, Shalaby, M, Shams, N, Sharma, A, Sharma, G, Shukla, A, Shussman, N, Shweejawee, Z, Sielezneff, I, Sigurdsson, H, Sileri, P, Silva, M, Simcikas, D, Simoes, J, Simonka, Z, Singh, B, Sivins, A, Skroubis, G, Skull, A, Slavchev, M, Slavin, M, Smart, N, Smart, C, Smart, P, Smedh, K, Smolarek, S, Sokmen, S, Sokolov, M, Solana Bueno, A, Solar, L, Sorrentino, L, Sotona, O, Spacca, D, Spinelli, A, Stanojevic, G, Stearns, A, Stefan, S, Stift, A, Stijns, J, Stoyanov, V, Straarup, D, Strupas, K, Stubbs, B, Subocius, A, Sudlow, A, Suero, C, Sungurtekin, U, Svagzdys, S, Syk, I, Tamelis, A, Tamhane, R, Tamini, N, Tamosiunas, A, Tanis, P, Tarasov, N, Tate, S, Tennakoon, A, Teo, N, Terzi, C, Tezas, S, Thabet, W, Tham, J, Thavanesan, N, Theodosopoulos, T, Thomas, W, Tiret, E, Tiselius, C, Todorov, G, Tomazic, A, Tomulescu, V, Torkington, J, Totis, M, Trostchansky, I, Truan, N, Tulchinsky, H, Tutino, R, Tzivanakis, A, Tzovaras, G, Ugolini, G, Unger, L, Upanishad, I, Urbani, L, Uth Ovesen, A, Vaizey, C, Vallribera, F, Valsdottir, E, Valverde, I, Valverde-Sintas, J, Van Belle, K, Van Cleven, S, van Hagen, P, van Loon, Y, van Ruler, O, Van Wijck, K, Varabei, A, Varcada, M, Varpe, P, Vartic, M, Velchuru, V, Vencius, J, Venskutonis, D, Vercher, D, Vermaas, M, Vertruyen, M, Verza, L, Vescio, G, Vezakis, A, Vieira, P, Vignali, A, Vigorita, V, Vila Tura, M, Vinson-Bonnet, B, Viso Pons, L, Voloshin, S, Voronin, Y, Vukusic, L, Wang, X, Wang, J, Wani, R, Warusavitarne, J, Wasserberg, N, Weerts, J, Weiss, D, Weizman, A, Westerduin, E, Wheat, J, White, I, Wik, T, Wilson, J, Winter, D, Wolthuis, A, Wong, M, Yahia, S, Yamamoto, T, Yanishev, A, Yao, C, Yildiz, A, Yuksel, O, Zain, Z, Zakaria, A, Zakaria, Z, Zampitis, N, Zarand, A, Zarco-Pleguezuelos, A, Zattoni, D, Zelic, M, Zeromskas, P, Zhuravlev, A, Zimmerman, D, Zuhdy, M, Zukanovic, G, Pinkney T.D., Taylor H., Tong C., Schmitz N.-D., Morton D.G., Bhangu A., Blackwell S., Dardanov D., Dulskas A., Gallo G., Glasbey J., Keatley J., Knowles C., Li Y.E., McCourt V., Minaya-Bravo A., Neary P., Nepogodiev D., Pata F., Pellino G., Sivrikoz E., van Ramshorst G., Zmora O., Perry R., Magill E.L., Abdalkoddus M., Abelevich A., Abraham S., Abraham-Nordling M., Adamina M., Agalar C., Agresta F., Ahallat M., Ahmad N., Aiupov R., Akca O., Aleksic A., Aleotti F., Alias D., Alonso J., Alonso Goncalves S., Alonso Martin J., Alonso Poza A., Alonso-Hernandez N., Alos Company R., Al-Saeedi M., Alvarez-Laso C., Alvarez-Gallego M., Amanatidis T., Americano M., Amorim E., Anandan L., Anania G., Ancans G., Andreev P., Andrejevic P., Antonacci N., Anwer M., Aonzo P., Arencibia B., Argeny S., Arieli H., Arnold S., Ashraf M., Aslam M., Atanasov B., Atif M., Atladottir J., Avital S., Awny S., Aytac B., Azahr N., Aznar-Puig S., Bailey S., Balalis D., Baldi C., Baldonedo R., Balducci G., Balestra F., Balestri R., Balfour A., Baloyiannis I., Banky B., Baral J., Baranyai Z., Barbashinov N., Bargallo J., Barisic G., Barugola G., Batashki I., Battersby N., Belev N., Belli A., Beltran de Heredia J., Bemelman W., Benavides Buleje J., Benckert A., Bernal-Sprekelsen J., Bertocchi E., Beuran M., Bhan C., Bianco F., Bilali S., Bilali V., Bintintan V., Birindelli A., Birsan T., Blanco Antona F., Blas J., Blasco-Segura T., Blom R., Bocchetti T., Boerma E., Bogdan M., Boland M., Bomans B., Borda N., Bowen M., Bradulskis S., Branagan G., Brankovic B., Brenna M., Brewer H., Broadhurst J., Bronder C., Brouwer R., Buccianti P., Buchs N., Buchwald P., Bugatti A., Bui A., Burcos T., Buskens C., Bustamante C., Caceres N., Cagigas Fernandez C., Calero-Lillo A., Camps I., Canda A., Caravaca-Garcia I., Carballo F., Carcoforo P., Carlander J., Carlos S., Caro A., Carpelan A., Carrasco Prats M., Carrillo Lopez M., Carvello M., Casal E., Casoni Pattacini G., Castellvi Valls J., Castillo Diego J., Cavallesco G., Cavenaile V., Cayetano L., Ceccotti A., Cervera-Aldama J., Chabok A., Chafai N., Chandrasinghe P., Chandratreya N., Chaudhri S., Chaudhry Z., Cherdancev D., Chernov A., Chevallay M., Chirletti P., Chouillard E., Chouliaras C., Chowdri N., Cillo M., Cini C., Ciubotaru C., Ciuce C., Claeys D., Cocorullo G., Codina-Cazador A., Colak E., Coletta D., Colombo F., Copaescu C., Corte Real J., Corver M., Cosic J., Costa S., Costa Pereira J., Costa Pereira C., Costa-Navarro D., Cotte E., Cracco N., Cristian D., Cuadrado M., Cuk V., Cunha M., Cunha J., Curinga R., Curletti G., Curtis N., Dabic D., Dainius E., d'Alessandro A., Daniels I., Darvin V., Dauser B., David G., Davidova O., Davies E., de Andres Asenjo B., De franciscis S., de Graaf E., De la Portilla F., De Luca E., De Nisco C., De Toma G., Defoort B., Den Boer F., Di Candido F., Di Saverio S., Diaz Pavon J., Dieguez Fernandez B., Diez-Alonso M., Dimitrijevic I., Dindelegan G., Djuric M., Domingos H., Doornebosch P., Dos Santos M., Drami I., Dudarovaska H., Dusek T., Dzhumabaev H., Eden Y., Egenvall M., Eismiontas V., El Sorogy M., Elgeidie A., Elhemaly M., El-Hussuna A., Ellul S., Elmore U., ElNakeeb A., Elrefai M., Emile S., Enrriquez-Navascues J., Epstein J., Escartin J., Escola D., Escuder J., Espin E., Espina B., Estefania D., Etienne J., Fabbri S., Falato A., Fares R., Farina P., Farkasova M., Farres R., Fasolini F., Fatayer T., Febles G., Feliu F., Feo C., Feoktistov D., Fernandez F., Fernandez Isart M., Fernando J., Ferreira G., Ferrer R., Ferreras Garcia C., Ferri M., Figueiredo N., Finotti E., Fitzgerald J., Flateh Backe I., Flor-Lorente B., Forero-Torres A., Foschi D., Francart D., Francois Y., Frasson M., Freil-Lanter C., Frois Borges M., Fuzun M., Gala T., Galleano R., Galvez P., Galvez Saldana A., Gamundi Cuesta M., Garcia Cabrera A., Garcia Egea J., Garcia Olmo D., Garcia-Gonzalez J., Garcia-Granero A., Garcia-Granero E., Garcia-Septiem J., Gardea A., Garipov M., Gefen R., Geraghty A., Gerkis S., Germanos S., Ghaffari S., Ghilles E., Gianotti L., Gil Santos M., Gilsanz Martin C., Gingert C., Gklavas A., Glehen O., Golda T., Gomez N., Gomez R., Gomez Ruiz M., Gonzalez Santin V., Graham B., Grainger J., Grama F., Gregoir T., Gregori M., Grolich T., Grosek J., Guadalajara H., Guckenheimer S., Guevara J., Gulotta G., Gupta S., Gurevich N., Gurjar S., Haapaniemi S., Hahnloser D., Hamad Y., Hamid M., Hanly A., Harris G., Harsanyi L., Hartig N., Hawkin P., Henriques P., Herbst F., Hermann N., Hernandez Garcia M., Hoch J., Hrora A., Huhtinen H., Iarumov N., Ilkanich A., Insua C., Ioannidis P., Iqbal M., Iqbal A., Isik A., Ismaiel M., Ivlev D., Jadhav V., Jareno S., Jehaes C., Jimenez V., Jimenez-Toscano M., Jimenez-Miramon J., Jimenez-Rodriguez R., Jonsson T., Jotautas V., Julia D., Juloski J., Jung B., Kala Z., Kalayci M., Kara Y., Karachun A., Karagul S., Karvonen J., Katorkin S., Katsoulis I., Katsounis D., Kaubrys M., Kaul N., Kefalou E., Keijzers M., Kelly M., Kenic M., Kennelly R., Khan J., Khan M., Kho H., Kinas V., Knight J., Kocian P., Koeter T., Kokobelyan A., Konsten J., Koolen L., Kosir J., Kostic I., Krdzic I., Kreisler Moreno E., Krivokapic Z., Krstev P., Krsul D., Kumarasinghe N., La Torre F., Labarga F., Ladra M., Lage Laredo A., Lahodzich N., Lai C., Lakkis Z., Lal R., Lamas S., Lang T., Latkauskas T., Lawes D., Lazar G., Lebedev K., Lebedeva M., Lefevre J., Lekic Vitlov V., Lemma M., Leo C., Leon C., Leventoglu S., Levy B., Li L., Licari L., Lizdenis P., Loftas P., Longhi M., Longstaff L., Lopez Dominguez J., Lopez-Lara M., Lora P., Lorenzon L., Lorusso D., Lozev I., Lozoya Trujillo R., Lukic D., Lunins R., Luzan R., Luzzi A., Maderuelo V., Madsboll T., Mahotin D., Majbar M., Makhmudov A., Malik K., Maly O., Mamaloudis I., Mamedli Z., Manatakis D., Mandi D., Mangell P., Marharint T., Mariani N., Maric B., Marimuthu K., Marinello F., Marino F., Markiewicz S., Markovic V., Marom G., Maroni N., Maroulis I., Marsanic P., Marsman H., Martens M., Marti M., Martinek L., Martinez S., Martinez D., Martinez Manzano A., Martins R., Maslyankov S., McArdle K., McDermott F., Mege D., Mehraj A., Mehta A., Mendrila D., Menendez P., Mercantini P., Metwally I., Mikalauskas S., Millan M., Mingoli A., Mirshekar-Syahkal B., Moggia E., Mohan S., Moller P., Mompart Garcia S., Monami B., Moniz Pereira P., Montroni I., Morel P., Moshev B., Mostovoy E., Mothe S., Mukhtar H., Muller P., Munch S., Munoz Camarena J., Munoz-Collado S., Muratore A., Muscara F., Muysoms F., Myrelid P., N.Lah N., Nail S., Narayanan A., Nastos K., Negoi I., Nesbakken A., Nestler G., Nestorovic M., Nesytykh A., Newton K., Ng Y., Ngu J., Nguyen B., Nijs Y., Nikberg M., Nimmersgern T., Nogues E., Norcic G., Nutautiene V., Nygren J., O'Brien J., Ochogavia Segui A., O'Kelly J., Oliveira-Cunha M., Omar W., Omar G., Onishchenko S., Onody P., Opocher E., Orhalmi J., Oshowo A., Otero J., Ozgen U., Pace K., Padin H., Papaconstantinou I., Papadopoulos A., Papadopoulos G., Papandrea M., Paral J., Parc Y., Paredes J., Parmar M., Parra Banos P., Parray F., Pascual Damieta M., Pascual Miguelanez I., Passot G., Pastor C., Paszt A., Patel P., Paterson H., Patron Uriburu J., Paulos A., Pavlov V., Pcolkins A., Pecic V., Pena Ros E., Penkov R., Pera Roman M., Perunicic V., Pery R., Petrovic D., Pezzolla F., Photi E., Pikarsky A., Piramanayagam B., Pisani Ceretti A., Planellas P., Platt E., Pletinckx P., Podda M., Poskus T., Poskus E., Pozdnyakov A., Pravosudov I., Previsic A., Prieto D., Prochazka V., Prodan A., Proud D., Psaila J., Psaras G., Pulighe F., Pullig F., Qureshi M., Rachadell J., Radovanovic Z., Radovanovic D., Raguan B., Rahman M., Raiss M., Ramirez Faraco M., Ramos J., Ramos-Prada J., Rantala A., Rao M., Rasulov A., Ratnatunga K., Raymond T., Refky B., Reggiani L., Regusci L., Reyes Diaz M., Richardson J., Richiteanu G., Rios A., Ris F., Rodriguez Garcia P., Roffi N., Romairone E., Romano G., Romero I., Romero de Diego A., Romero-Simo M., Roque C., Rosati R., Rossi B., Rossi E., Rossini R., Ruano A., Rubbini M., Rubio-Perez I., Ruffo G., Ruiz H., Ruiz Carmona M., Ryska O., Sabia D., Sacchi M., Sacco R., Sakr A., Saladzinskas Z., Salamone G., Salomon M., Salvans Ruiz S., Sammarco G., Sampietro G., Samsonov D., Samsonyuk V., Sanchez J., Sanchez Romero A., Sanchez-Guillen L., Santak G., Santamaria-Olabarrieta M., Santos J., Saraceno F., Saralegui Y., Sarici I., Savino G., Scabini S., Schafli J., Schiltz B., Schofield A., Schon M., Scurtu R., Segalini E., Segelman J., Segura-Sampedro J., Seicean R., Sekulic A., Selniahina L., Seretis F., Serrano Paz P., Shaikh I., Shalaby M., Shams N., Sharma A., Sharma G., Shukla A., Shussman N., Shweejawee Z., Sielezneff I., Sigurdsson H., Sileri P., Silva M., Simcikas D., Simoes J., Simonka Z., Singh B., Sivins A., Skroubis G., Skull A., Slavchev M., Slavin M., Smart N., Smart C., Smart P., Smedh K., Smolarek S., Sokmen S., Sokolov M., Solana Bueno A., Solar L., Sorrentino L., Sotona O., Spacca D., Spinelli A., Stanojevic G., Stearns A., Stefan S., Stift A., Stijns J., Stoyanov V., Straarup D., Strupas K., Stubbs B., Subocius A., Sudlow A., Suero C., Sungurtekin U., Svagzdys S., Syk I., Tamelis A., Tamhane R., Tamini N., Tamosiunas A., Tanis P., Tarasov N., Tate S., Tennakoon A., Teo N., Terzi C., Tezas S., Thabet W., Tham J., Thavanesan N., Theodosopoulos T., Thomas W., Tiret E., Tiselius C., Todorov G., Tomazic A., Tomulescu V., Torkington J., Totis M., Trostchansky I., Truan N., Tulchinsky H., Tutino R., Tzivanakis A., Tzovaras G., Ugolini G., Unger L., Upanishad I., Urbani L., Uth Ovesen A., Vaizey C., Vallribera F., Valsdottir E., Valverde I., Valverde-Sintas J., Van Belle K., Van Cleven S., van Hagen P., van Loon Y., van Ruler O., Van Wijck K., Varabei A., Varcada M., Varpe P., Vartic M., Velchuru V., Vencius J., Venskutonis D., Vercher D., Vermaas M., Vertruyen M., Verza L., Vescio G., Vezakis A., Vieira P., Vignali A., Vigorita V., Vila Tura M., Vinson-Bonnet B., Viso Pons L., Voloshin S., Voronin Y., Vukusic L., Wang X., Wang J., Wani R., Warusavitarne J., Wasserberg N., Weerts J., Weiss D., Weizman A., Westerduin E., Wheat J., White I., Wik T., Wilson J., Winter D., Wolthuis A., Wong M., Yahia S., Yamamoto T., Yanishev A., Yao C., Yildiz A., Yuksel O., Zain Z., Zakaria A., Zakaria Z., Zampitis N., Zarand A., Zarco-Pleguezuelos A., Zattoni D., Zelic M., Zeromskas P., Zhuravlev A., Zimmerman D., Zuhdy M., Zukanovic G., Pinkney, T. D., Taylor, H., Tong, C., Schmitz, N. -D., Morton, D. G., Bhangu, A., Blackwell, S., Dardanov, D., Dulskas, A., Gallo, G., Glasbey, J., Keatley, J., Knowles, C., Li, Y. E., Mccourt, V., Minaya-Bravo, A., Neary, P., Nepogodiev, D., Pata, F., Pellino, G., Sivrikoz, E., van Ramshorst, G., Zmora, O., Perry, R., Magill, E. L., Abdalkoddus, M., Abelevich, A., Abraham, S., Abraham-Nordling, M., Adamina, M., Agalar, C., Agresta, F., Ahallat, M., Ahmad, N., Aiupov, R., Akca, O., Aleksic, A., Aleotti, F., Alias, D., Alonso, J., Alonso Goncalves, S., Alonso Martin, J., Alonso Poza, A., Alonso-Hernandez, N., Alos Company, R., Al-Saeedi, M., Alvarez-Laso, C., Alvarez-Gallego, M., Amanatidis, T., Americano, M., Amorim, E., Anandan, L., Anania, G., Ancans, G., Andreev, P., Andrejevic, P., Antonacci, N., Anwer, M., Aonzo, P., Arencibia, B., Argeny, S., Arieli, H., Arnold, S., Ashraf, M., Aslam, M., Atanasov, B., Atif, M., Atladottir, J., Avital, S., Awny, S., Aytac, B., Azahr, N., Aznar-Puig, S., Bailey, S., Balalis, D., Baldi, C., Baldonedo, R., Balducci, G., Balestra, F., Balestri, R., Balfour, A., Baloyiannis, I., Banky, B., Baral, J., Baranyai, Z., Barbashinov, N., Bargallo, J., Barisic, G., Barugola, G., Batashki, I., Battersby, N., Belev, N., Belli, A., Beltran de Heredia, J., Bemelman, W., Benavides Buleje, J., Benckert, A., Bernal-Sprekelsen, J., Bertocchi, E., Beuran, M., Bhan, C., Bianco, F., Bilali, S., Bilali, V., Bintintan, V., Birindelli, A., Birsan, T., Blanco Antona, F., Blas, J., Blasco-Segura, T., Blom, R., Bocchetti, T., Boerma, E., Bogdan, M., Boland, M., Bomans, B., Borda, N., Bowen, M., Bradulskis, S., Branagan, G., Brankovic, B., Brenna, M., Brewer, H., Broadhurst, J., Bronder, C., Brouwer, R., Buccianti, P., Buchs, N., Buchwald, P., Bugatti, A., Bui, A., Burcos, T., Buskens, C., Bustamante, C., Caceres, N., Cagigas Fernandez, C., Calero-Lillo, A., Camps, I., Canda, A., Caravaca-Garcia, I., Carballo, F., Carcoforo, P., Carlander, J., Carlos, S., Caro, A., Carpelan, A., Carrasco Prats, M., Carrillo Lopez, M., Carvello, M., Casal, E., Casoni Pattacini, G., Castellvi Valls, J., Castillo Diego, J., Cavallesco, G., Cavenaile, V., Cayetano, L., Ceccotti, A., Cervera-Aldama, J., Chabok, A., Chafai, N., Chandrasinghe, P., Chandratreya, N., Chaudhri, S., Chaudhry, Z., Cherdancev, D., Chernov, A., Chevallay, M., Chirletti, P., Chouillard, E., Chouliaras, C., Chowdri, N., Cillo, M., Cini, C., Ciubotaru, C., Ciuce, C., Claeys, D., Cocorullo, G., Codina-Cazador, A., Colak, E., Coletta, D., Colombo, F., Copaescu, C., Corte Real, J., Corver, M., Cosic, J., Costa, S., Costa Pereira, J., Costa Pereira, C., Costa-Navarro, D., Cotte, E., Cracco, N., Cristian, D., Cuadrado, M., Cuk, V., Cunha, M., Cunha, J., Curinga, R., Curletti, G., Curtis, N., Dabic, D., Dainius, E., D'Alessandro, A., Daniels, I., Darvin, V., Dauser, B., David, G., Davidova, O., Davies, E., de Andres Asenjo, B., De franciscis, S., de Graaf, E., De la Portilla, F., De Luca, E., De Nisco, C., De Toma, G., Defoort, B., Den Boer, F., Di Candido, F., Di Saverio, S., Diaz Pavon, J., Dieguez Fernandez, B., Diez-Alonso, M., Dimitrijevic, I., Dindelegan, G., Djuric, M., Domingos, H., Doornebosch, P., Dos Santos, M., Drami, I., Dudarovaska, H., Dusek, T., Dzhumabaev, H., Eden, Y., Egenvall, M., Eismiontas, V., El Sorogy, M., Elgeidie, A., Elhemaly, M., El-Hussuna, A., Ellul, S., Elmore, U., Elnakeeb, A., Elrefai, M., Emile, S., Enrriquez-Navascues, J., Epstein, J., Escartin, J., Escola, D., Escuder, J., Espin, E., Espina, B., Estefania, D., Etienne, J., Fabbri, S., Falato, A., Fares, R., Farina, P., Farkasova, M., Farres, R., Fasolini, F., Fatayer, T., Febles, G., Feliu, F., Feo, C., Feoktistov, D., Fernandez, F., Fernandez Isart, M., Fernando, J., Ferreira, G., Ferrer, R., Ferreras Garcia, C., Ferri, M., Figueiredo, N., Finotti, E., Fitzgerald, J., Flateh Backe, I., Flor-Lorente, B., Forero-Torres, A., Foschi, D., Francart, D., Francois, Y., Frasson, M., Freil-Lanter, C., Frois Borges, M., Fuzun, M., Gala, T., Galleano, R., Galvez, P., Galvez Saldana, A., Gamundi Cuesta, M., Garcia Cabrera, A., Garcia Egea, J., Garcia Olmo, D., Garcia-Gonzalez, J., Garcia-Granero, A., Garcia-Granero, E., Garcia-Septiem, J., Gardea, A., Garipov, M., Gefen, R., Geraghty, A., Gerkis, S., Germanos, S., Ghaffari, S., Ghilles, E., Gianotti, L., Gil Santos, M., Gilsanz Martin, C., Gingert, C., Gklavas, A., Glehen, O., Golda, T., Gomez, N., Gomez, R., Gomez Ruiz, M., Gonzalez Santin, V., Graham, B., Grainger, J., Grama, F., Gregoir, T., Gregori, M., Grolich, T., Grosek, J., Guadalajara, H., Guckenheimer, S., Guevara, J., Gulotta, G., Gupta, S., Gurevich, N., Gurjar, S., Haapaniemi, S., Hahnloser, D., Hamad, Y., Hamid, M., Hanly, A., Harris, G., Harsanyi, L., Hartig, N., Hawkin, P., Henriques, P., Herbst, F., Hermann, N., Hernandez Garcia, M., Hoch, J., Hrora, A., Huhtinen, H., Iarumov, N., Ilkanich, A., Insua, C., Ioannidis, P., Iqbal, M., Iqbal, A., Isik, A., Ismaiel, M., Ivlev, D., Jadhav, V., Jareno, S., Jehaes, C., Jimenez, V., Jimenez-Toscano, M., Jimenez-Miramon, J., Jimenez-Rodriguez, R., Jonsson, T., Jotautas, V., Julia, D., Juloski, J., Jung, B., Kala, Z., Kalayci, M., Kara, Y., Karachun, A., Karagul, S., Karvonen, J., Katorkin, S., Katsoulis, I., Katsounis, D., Kaubrys, M., Kaul, N., Kefalou, E., Keijzers, M., Kelly, M., Kenic, M., Kennelly, R., Khan, J., Khan, M., Kho, H., Kinas, V., Knight, J., Kocian, P., Koeter, T., Kokobelyan, A., Konsten, J., Koolen, L., Kosir, J., Kostic, I., Krdzic, I., Kreisler Moreno, E., Krivokapic, Z., Krstev, P., Krsul, D., Kumarasinghe, N., La Torre, F., Labarga, F., Ladra, M., Lage Laredo, A., Lahodzich, N., Lai, C., Lakkis, Z., Lal, R., Lamas, S., Lang, T., Latkauskas, T., Lawes, D., Lazar, G., Lebedev, K., Lebedeva, M., Lefevre, J., Lekic Vitlov, V., Lemma, M., Leo, C., Leon, C., Leventoglu, S., Levy, B., Li, L., Licari, L., Lizdenis, P., Loftas, P., Longhi, M., Longstaff, L., Lopez Dominguez, J., Lopez-Lara, M., Lora, P., Lorenzon, L., Lorusso, D., Lozev, I., Lozoya Trujillo, R., Lukic, D., Lunins, R., Luzan, R., Luzzi, A., Maderuelo, V., Madsboll, T., Mahotin, D., Majbar, M., Makhmudov, A., Malik, K., Maly, O., Mamaloudis, I., Mamedli, Z., Manatakis, D., Mandi, D., Mangell, P., Marharint, T., Mariani, N., Maric, B., Marimuthu, K., Marinello, F., Marino, F., Markiewicz, S., Markovic, V., Marom, G., Maroni, N., Maroulis, I., Marsanic, P., Marsman, H., Martens, M., Marti, M., Martinek, L., Martinez, S., Martinez, D., Martinez Manzano, A., Martins, R., Maslyankov, S., Mcardle, K., Mcdermott, F., Mege, D., Mehraj, A., Mehta, A., Mendrila, D., Menendez, P., Mercantini, P., Metwally, I., Mikalauskas, S., Millan, M., Mingoli, A., Mirshekar-Syahkal, B., Moggia, E., Mohan, S., Moller, P., Mompart Garcia, S., Monami, B., Moniz Pereira, P., Montroni, I., Morel, P., Moshev, B., Mostovoy, E., Mothe, S., Mukhtar, H., Muller, P., Munch, S., Munoz Camarena, J., Munoz-Collado, S., Muratore, A., Muscara, F., Muysoms, F., Myrelid, P., N. Lah, N., Nail, S., Narayanan, A., Nastos, K., Negoi, I., Nesbakken, A., Nestler, G., Nestorovic, M., Nesytykh, A., Newton, K., Ng, Y., Ngu, J., Nguyen, B., Nijs, Y., Nikberg, M., Nimmersgern, T., Nogues, E., Norcic, G., Nutautiene, V., Nygren, J., O'Brien, J., Ochogavia Segui, A., O'Kelly, J., Oliveira-Cunha, M., Omar, W., Omar, G., Onishchenko, S., Onody, P., Opocher, E., Orhalmi, J., Oshowo, A., Otero, J., Ozgen, U., Pace, K., Padin, H., Papaconstantinou, I., Papadopoulos, A., Papadopoulos, G., Papandrea, M., Paral, J., Parc, Y., Paredes, J., Parmar, M., Parra Banos, P., Parray, F., Pascual Damieta, M., Pascual Miguelanez, I., Passot, G., Pastor, C., Paszt, A., Patel, P., Paterson, H., Patron Uriburu, J., Paulos, A., Pavlov, V., Pcolkins, A., Pecic, V., Pena Ros, E., Penkov, R., Pera Roman, M., Perunicic, V., Pery, R., Petrovic, D., Pezzolla, F., Photi, E., Pikarsky, A., Piramanayagam, B., Pisani Ceretti, A., Planellas, P., Platt, E., Pletinckx, P., Podda, M., Poskus, T., Poskus, E., Pozdnyakov, A., Pravosudov, I., Previsic, A., Prieto, D., Prochazka, V., Prodan, A., Proud, D., Psaila, J., Psaras, G., Pulighe, F., Pullig, F., Qureshi, M., Rachadell, J., Radovanovic, Z., Radovanovic, D., Raguan, B., Rahman, M., Raiss, M., Ramirez Faraco, M., Ramos, J., Ramos-Prada, J., Rantala, A., Rao, M., Rasulov, A., Ratnatunga, K., Raymond, T., Refky, B., Reggiani, L., Regusci, L., Reyes Diaz, M., Richardson, J., Richiteanu, G., Rios, A., Ris, F., Rodriguez Garcia, P., Roffi, N., Romairone, E., Romano, G., Romero, I., Romero de Diego, A., Romero-Simo, M., Roque, C., Rosati, R., Rossi, B., Rossi, E., Rossini, R., Ruano, A., Rubbini, M., Rubio-Perez, I., Ruffo, G., Ruiz, H., Ruiz Carmona, M., Ryska, O., Sabia, D., Sacchi, M., Sacco, R., Sakr, A., Saladzinskas, Z., Salamone, G., Salomon, M., Salvans Ruiz, S., Sammarco, G., Sampietro, G., Samsonov, D., Samsonyuk, V., Sanchez, J., Sanchez Romero, A., Sanchez-Guillen, L., Santak, G., Santamaria-Olabarrieta, M., Santos, J., Saraceno, F., Saralegui, Y., Sarici, I., Savino, G., Scabini, S., Schafli, J., Schiltz, B., Schofield, A., Schon, M., Scurtu, R., Segalini, E., Segelman, J., Segura-Sampedro, J., Seicean, R., Sekulic, A., Selniahina, L., Seretis, F., Serrano Paz, P., Shaikh, I., Shalaby, M., Shams, N., Sharma, A., Sharma, G., Shukla, A., Shussman, N., Shweejawee, Z., Sielezneff, I., Sigurdsson, H., Sileri, P., Silva, M., Simcikas, D., Simoes, J., Simonka, Z., Singh, B., Sivins, A., Skroubis, G., Skull, A., Slavchev, M., Slavin, M., Smart, N., Smart, C., Smart, P., Smedh, K., Smolarek, S., Sokmen, S., Sokolov, M., Solana Bueno, A., Solar, L., Sorrentino, L., Sotona, O., Spacca, D., Spinelli, A., Stanojevic, G., Stearns, A., Stefan, S., Stift, A., Stijns, J., Stoyanov, V., Straarup, D., Strupas, K., Stubbs, B., Subocius, A., Sudlow, A., Suero, C., Sungurtekin, U., Svagzdys, S., Syk, I., Tamelis, A., Tamhane, R., Tamini, N., Tamosiunas, A., Tanis, P., Tarasov, N., Tate, S., Tennakoon, A., Teo, N., Terzi, C., Tezas, S., Thabet, W., Tham, J., Thavanesan, N., Theodosopoulos, T., Thomas, W., Tiret, E., Tiselius, C., Todorov, G., Tomazic, A., Tomulescu, V., Torkington, J., Totis, M., Trostchansky, I., Truan, N., Tulchinsky, H., Tutino, R., Tzivanakis, A., Tzovaras, G., Ugolini, G., Unger, L., Upanishad, I., Urbani, L., Uth Ovesen, A., Vaizey, C., Vallribera, F., Valsdottir, E., Valverde, I., Valverde-Sintas, J., Van Belle, K., Van Cleven, S., van Hagen, P., van Loon, Y., van Ruler, O., Van Wijck, K., Varabei, A., Varcada, M., Varpe, P., Vartic, M., Velchuru, V., Vencius, J., Venskutonis, D., Vercher, D., Vermaas, M., Vertruyen, M., Verza, L., Vescio, G., Vezakis, A., Vieira, P., Vignali, A., Vigorita, V., Vila Tura, M., Vinson-Bonnet, B., Viso Pons, L., Voloshin, S., Voronin, Y., Vukusic, L., Wang, X., Wang, J., Wani, R., Warusavitarne, J., Wasserberg, N., Weerts, J., Weiss, D., Weizman, A., Westerduin, E., Wheat, J., White, I., Wik, T., Wilson, J., Winter, D., Wolthuis, A., Wong, M., Yahia, S., Yamamoto, T., Yanishev, A., Yao, C., Yildiz, A., Yuksel, O., Zain, Z., Zakaria, A., Zakaria, Z., Zampitis, N., Zarand, A., Zarco-Pleguezuelos, A., Zattoni, D., Zelic, M., Zeromskas, P., Zhuravlev, A., Zimmerman, D., Zuhdy, M., and Zukanovic, G.
- Subjects
medicine.medical_specialty ,Prehabilitation ,medicine.medical_treatment ,MEDLINE ,Colorectal Neoplasm ,Perioperative Care ,NO ,medicine ,Humans ,03.02. Klinikai orvostan ,Perioperative Optimisation ,Enhanced recovery after surgery ,Digestive System Surgical Procedures ,LS7_4 ,Enhanced Recovery After Surgery (ERAS) ,business.industry ,Gastroenterology ,Digestive System Surgical Procedure ,Guideline ,Colorectal surgery ,Surgery ,Family medicine ,Perioperative care ,Nasogastric intubation ,Preoperative fasting ,Colorectal Neoplasms ,Enhanced Recovery After Surgery ,business ,Colorectal Surgery ,Human - Abstract
Aim The Enhanced Recovery After Surgery (ERAS® ) Society guidelines aim to standardise perioperative care in colorectal surgery via 25 principles. We aimed to assess the variation in uptake of these principles across an international network of colorectal units. Method An online survey was circulated amongst European Society of Coloproctology members in 2019/20. For each ERAS® principle, respondents were asked to score how frequently the principle was implemented in their hospital, from 1 ('rarely') to 4 ('always'). Respondents were also asked to recall whether practice had changed since 2017. Subgroup analyses based on hospital characteristics were conducted. Results Of hospitals approached, 58% responded to the survey (195/335), with 296 individual responses (multiple responses were received from some hospitals). The majority were European (163/195 [83.6%]). Overall, respondents indicated they 'most often' or 'always' adhered to most individual ERAS® principles (18/25 [72%]). Variability in uptake of principles was reported, with universal uptake of some principles (e.g., prophylactic antibiotics; early mobilisation) and inconsistency from 'rarely' to 'always' in others (e.g., no nasogastric intubation; no preoperative fasting and carbohydrate drinks). In alignment with 2018 ERAS® guideline updates, adherence to principles for prehabilitation, managing anaemia, and postoperative nutrition appears to have increased since 2017. Conclusions Uptake of ERAS® principles varied across hospitals, and not all 25 principles were equally adhered to. Whilst some principles exhibited a high level of acceptance, others had a wide variability in uptake indicative of controversy or barriers to uptake. Further research into specific principles is required to improve ERAS® implementation.
- Published
- 2021
38. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
- Author
-
Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, and Raspagliesi F
- Subjects
Olaparib ,Ovarian cancer ,PARP inhibitors ,Homologous Recombination Deficiency ,BRCA mutation ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Domenica Lorusso, Elisa Tripodi, Giuseppa Maltese, Stefano Lepori, Ilaria Sabatucci, Giorgio Bogani, Francesco Raspagliesi Gynecologic Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy Abstract: Epithelial ovarian cancer is the sixth most common cancer among women worldwide and the first cause of death among gynecological malignancies. Most of the patients present recurrent disease and unfortunately cannot be cured. The unsatisfactory results obtained with salvage chemotherapy have elicited investigators to search for novel biological agents capable of achieving a better control of the disease. In the setting of homologous recombination deficiency, the DNA errors that occur cannot be accurately repaired, and the treatment with poly(ADP-ribose) polymerase (PARP) inhibition results in definitive cell death in a process called synthetic lethality. As a result of two positive clinical trials, Olaparib was approved in 2014 by U.S. Food and Drug Administration and European Medicines Agency as the first-in-class PARP inhibitor. Olaparib is effective and well tolerated in homologous recombination deficient patients. Several studies with Olaparib have been conducted in the recurrent setting either as maintenance in platinum-responsive patients or as a single agent. Ongoing trials are focused on the use of olaparib as maintenance in the first-line ovarian cancer setting alone or in combination with antiangiogenic agents. Future perspectives will probably investigate the association of olaparib with novel agents as check-point inhibitors and PI3K-AKT inhibitors. The PARP inhibitor era is just at the beginning. Keywords: olaparib, ovarian cancer, PARP inhibitors, homologous recombination deficiency, BRCA mutation
- Published
- 2018
39. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- Author
-
Buck, M, Dean, A, Friedlander, M L, Goh, J C, Harnett, P, Kichenadasse, G, Scott, C L, Denys, H, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, A M, Plante, M, Provencher, D, Weberpals, J I, Welch, S, Floquet, A, Gladieff, L, Joly, F, Leary, A, Lortholary, A, Lotz, J, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Pignata, S, Sabbatini, R F, Scambia, G, Tamberi, S, Zamagni, C, Fong, P C, O'Donnell, A, Gancedo, M Amenedo, Herraez, A Casado, Garcia-Donas, J, Guerra, E M, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, S N, Clamp, A, Drew, Y, Gabra, H G, Jackson, D, Ledermann, J A, McNeish, I A, Parkinson, C, Powell, M, Aghajanian, C, Armstrong, D K, Birrer, M J, Buss, M K, Chambers, S K, Chen, L-m, Coleman, R L, Holloway, R W, Konecny, G E, Ma, L, Morgan, M A, Morris, R T, Mutch, D G, O'Malley, D M, Slomovitz, B M, Swisher, E M, Vanderkwaak, T, Vulfovich, M, Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, and Ledermann, Jonathan A
- Published
- 2017
- Full Text
- View/download PDF
40. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
- Author
-
Wilson, M.K., Pujade-Lauraine, E., Aoki, D., Mirza, M.R., Lorusso, D., Oza, A.M., du Bois, A., Vergote, I., Reuss, A., Bacon, M., Friedlander, M., Gallardo-Rincon, D., Joly, F., Chang, S.-J., Ferrero, A.M., Edmondson, R.J., Wimberger, P., Maenpaa, J., Gaffney, D., Zang, R., Okamoto, A., Stuart, G., and Ochiai, K.
- Published
- 2017
- Full Text
- View/download PDF
41. The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study
- Author
-
Mangili, G., Sigismondi, C., Lorusso, D., Cormio, G., Candiani, M., Scarfone, G., Mascilini, F., Gadducci, A., Mosconi, A.M., Scollo, P., Cassani, C., Pignata, S., and Ferrandina, G.
- Published
- 2017
- Full Text
- View/download PDF
42. Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age
- Author
-
Colombo, N, Oza, A M, Lorusso, D, Aghajanian, C, Oaknin, A, Dean, A, Weberpals, J I, Clamp, A R, Scambia, G, Leary, A, Holloway, R W, Gancedo, Amenedo M, Fong, P C, Goh, J C, OʼMalley, D M, Armstrong, D K, Banerjee, S, García-Donas, J, Swisher, E M, Meunier, J, Cameron, T, Maloney, L, Goble, S, Bedel, J, Coleman, R L, and Ledermann, J A
- Published
- 2019
- Full Text
- View/download PDF
43. Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3
- Author
-
Clamp, A R, Oza, A M, Lorusso, D, Aghajanian, C, Oaknin, A, Dean, A, Colombo, N, Weberpals, J I, Scambia, G, Leary, A, Holloway, R W, Gancedo, Amenedo M, Fong, P C, Goh, J C, OʼMalley, D M, Armstrong, D K, Banerjee, S, García-Donas, J, Swisher, E M, Cameron, T, Maloney, L, Goble, S, Coleman, R L, and Ledermann, J A
- Published
- 2019
- Full Text
- View/download PDF
44. Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial
- Author
-
Mirza, M R, Dørum, A, Benigno, B, Mahner, S, Bessette, P, Barcelo, Bover IM, Berton, D, Ledermann, J, Rimel, B J, Herrstedt, J, Lau, S, Canzler, U, Vázquez, Palacio I, Kalbacher, E, Buscema, J, Lorusso, D, Debruyne, P, Bruchim, I, Guo, W, Gupta, D, de Jong, F A, and Matulonis, U A
- Published
- 2019
- Full Text
- View/download PDF
45. Clear cell carcinoma of the endometrium
- Author
-
Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Enomoto, T, Takehara, K, Denys, H, Lorusso, D, Coleman, R, Vaughan, M, Takano, M, Provencher, D, Sagae, S, Wimberger, P, Poka, R, Segev, Y, Kim, S, Kim, J, Candido dos Reis, F, Mariani, A, Leitao, M, Makker, V, Rustum, N, Vergote, I, Zannoni, G, Tan, D, Mccormack, M, Bini, M, Lopez, S, Raspagliesi, F, Panici, P, di Donato, V, Muzii, L, Colombo, N, Scambia, G, Pignata, S, Monk, B, Bogani G., Ray-Coquard I., Concin N., Ngoi N. Y. L., Morice P., Enomoto T., Takehara K., Denys H., Lorusso D., Coleman R., Vaughan M. M., Takano M., Provencher D., Sagae S., Wimberger P., Poka R., Segev Y., Kim S. I., Kim J. -W., Candido dos Reis F. J., Mariani A., Leitao M. M., Makker V., Rustum N. A., Vergote I., Zannoni G. F., Tan D. S. P., McCormack M., Bini M., Lopez S., Raspagliesi F., Panici P. B., di Donato V., Muzii L., Colombo N., Scambia G., Pignata S., Monk B. J., Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Enomoto, T, Takehara, K, Denys, H, Lorusso, D, Coleman, R, Vaughan, M, Takano, M, Provencher, D, Sagae, S, Wimberger, P, Poka, R, Segev, Y, Kim, S, Kim, J, Candido dos Reis, F, Mariani, A, Leitao, M, Makker, V, Rustum, N, Vergote, I, Zannoni, G, Tan, D, Mccormack, M, Bini, M, Lopez, S, Raspagliesi, F, Panici, P, di Donato, V, Muzii, L, Colombo, N, Scambia, G, Pignata, S, Monk, B, Bogani G., Ray-Coquard I., Concin N., Ngoi N. Y. L., Morice P., Enomoto T., Takehara K., Denys H., Lorusso D., Coleman R., Vaughan M. M., Takano M., Provencher D., Sagae S., Wimberger P., Poka R., Segev Y., Kim S. I., Kim J. -W., Candido dos Reis F. J., Mariani A., Leitao M. M., Makker V., Rustum N. A., Vergote I., Zannoni G. F., Tan D. S. P., McCormack M., Bini M., Lopez S., Raspagliesi F., Panici P. B., di Donato V., Muzii L., Colombo N., Scambia G., Pignata S., and Monk B. J.
- Abstract
Clear cell endometrial carcinoma represents an uncommon and poorly understood entity. Data from molecular/genomic profiling highlighted the importance of various signatures in assessing the prognosis of endometrial cancer according to four classes of risk (POLE mutated, MMRd, NSMP, and p53 abnormal). Unfortunately, data specific to clear cell histological subtype endometrial cancer are lacking. More recently, data has emerged to suggest that most of the patients (more than 80%) with clear cell endometrial carcinoma are characterized by p53 abnormality or NSMP type. This classification has important therapeutic implications. Although it is an uncommon entity, clear cell endometrial cancer patients with POLE mutation seem characterized by a good prognosis. Chemotherapy is effective in patients with NSMP (especially in stage III and IV) and patients with p53 abnormal disease (all stages). While, preliminary data suggested that patients with MMRd are less likely to benefit from chemotherapy. The latter group appears to benefit much more from immune checkpoint inhibitors: recent data from clinical trials on pembrolizumab plus lenvatinib and nivolumab plus cabozantinib supported that immunotherapy plus tyrosine kinase inhibitors (TKI) would be the most appropriate treatment for recurrent non-endometrioid endometrial cancer (including clear cell carcinoma) after the failure of platinum-based chemotherapy. Moreover, ongoing clinical trials testing the anti-tumor activity of innovative products will clarify the better strategies for advanced/recurrent clear cell endometrial carcinoma. Further prospective evidence is urgently needed to better characterize clear cell endometrial carcinoma.
- Published
- 2022
46. Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients
- Author
-
D'Alterio, C, Spina, A, Arenare, L, Chiodini, P, Napolitano, M, Galdiero, F, Portella, L, Simeon, V, Signoriello, S, Raspagliesi, F, Lorusso, D, Pisano, C, Colombo, N, Zannoni, G, Losito, N, De Cecio, R, Scognamiglio, G, Califano, D, Russo, D, Tuninetti, V, Piccirillo, M, Gargiulo, P, Perrone, F, Pignata, S, Scala, S, D'alterio C., Spina A., Arenare L., Chiodini P., Napolitano M., Galdiero F., Portella L., Simeon V., Signoriello S., Raspagliesi F., Lorusso D., Pisano C., Colombo N., Zannoni G. F., Losito N. S., De Cecio R., Scognamiglio G., Califano D., Russo D., Tuninetti V., Piccirillo M. C., Gargiulo P., Perrone F., Pignata S., Scala S., D'Alterio, C, Spina, A, Arenare, L, Chiodini, P, Napolitano, M, Galdiero, F, Portella, L, Simeon, V, Signoriello, S, Raspagliesi, F, Lorusso, D, Pisano, C, Colombo, N, Zannoni, G, Losito, N, De Cecio, R, Scognamiglio, G, Califano, D, Russo, D, Tuninetti, V, Piccirillo, M, Gargiulo, P, Perrone, F, Pignata, S, Scala, S, D'alterio C., Spina A., Arenare L., Chiodini P., Napolitano M., Galdiero F., Portella L., Simeon V., Signoriello S., Raspagliesi F., Lorusso D., Pisano C., Colombo N., Zannoni G. F., Losito N. S., De Cecio R., Scognamiglio G., Califano D., Russo D., Tuninetti V., Piccirillo M. C., Gargiulo P., Perrone F., Pignata S., and Scala S.
- Abstract
This study investigated the prognostic role of the CXCR4-CXCL12-CXCR7 axis in advanced epithelial ovarian cancer (EOC) patients receiving first-line treatment within the MITO16A/MaNGO-OV2 phase-IV trial. CXCR4-CXCL12-CXCR7 expression was evaluated in the epithelial and stromal component of 308 EOC IHC-stained tumor samples. The statistical analysis focused on biomarkers’ expression, their association with other variables and prognostic value. Zero-inflated tests, shrinkage, bootstrap procedures, and multivariable models were applied. The majority of EOC (75.0%) expressed CXCR4 and CXCR7, 56.5% expressed the entire CXCR4-CXCL12-CXCR7 axis, while only 4.6% were negative for CXCL12 and its cognate receptors, in regard to the epithelial component. Stromal CXCL12 and CXCR7, expressed in 11.2% and 65.5%, respectively, were associated with the FIGO stage. High CXCL12 in epithelial cancer cells was associated with shorter progression-free and overall survival. However, after adjusting for overfitting due to best cut-off multiplicity testing, the significance was lost. This is a wide-ranging, prospective study in which CXCR4-CXCL12-CXCR7 were systematically evaluated in epithelial and stromal components, in selected stage III-IV EOC. Although CXCL12 was not prognostic, epithelial expression identified high-risk FIGO stage III patients for PFS. These data suggest that it might be worth studying the CXCL12 axis as a therapeutic target to improve treatment efficacy in EOC patients.
- Published
- 2022
47. Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study
- Author
-
Mosconi, P, Roberto, A, Cerana, N, Colombo, N, Didier, F, D'Incalci, M, Lorusso, D, Peccatori, F, Mosconi P., Roberto A., Cerana N., Colombo N., Didier F., D'Incalci M., Lorusso D., Peccatori F. A., Mosconi, P, Roberto, A, Cerana, N, Colombo, N, Didier, F, D'Incalci, M, Lorusso, D, Peccatori, F, Mosconi P., Roberto A., Cerana N., Colombo N., Didier F., D'Incalci M., Lorusso D., and Peccatori F. A.
- Abstract
BACKGROUND: Despite several initiatives by research groups, regulatory authorities, and scientific associations to engage citizens/patients in clinical research, there are still obstacles to participation. Among the main discouraging aspects are incomplete understanding of the concepts related to a clinical trial, and the scant, sometimes confused, explanations given. This observational, cross-sectional multicenter study investigated knowledge, attitudes and trust in clinical research. We conducted a survey among women with ovarian cancer at their first follow-up visit or first therapy session, treated in centers belonging to the Mario Negri Gynecologic Oncology (MaNGO) and Multicenter Italian Trials in Ovarian Cancer (MITO) groups. A questionnaire on knowledge, attitudes and experience was assembled ad hoc after a literature review and a validation process involving patients of the Alliance against Ovarian Cancer (ACTO). RESULTS: From 25 centers 348 questionnaire were collected; 73.5% of responders were 56 years or older, 54.8% had a high level of education, more than 80% had no experience of trial participation. Among participants 59% knew what clinical trials were and 71% what informed consent was. However, more than half did not know the meaning of the term randomization. More than half (56%) were in favor of participating in a clinical trial, but 35% were not certain. Almost all responders acknowledged the doctor's importance in decision-making. Patients' associations were recognized as having a powerful role in the design and planning of clinical trials. CONCLUSIONS: This study helps depict the knowledge and attitudes of women with ovarian cancer in relation to clinical trials, suggesting measures aimed at improving trial "culture", literacy and compliance, and fresh ways of communication between doctors and patients.
- Published
- 2022
48. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
- Author
-
O'Malley, D, Oza, A, Lorusso, D, Aghajanian, C, Oaknin, A, Dean, A, Colombo, N, Weberpals, J, Clamp, A, Scambia, G, Leary, A, Holloway, R, Gancedo, M, Fong, P, Goh, J, Swisher, E, Maloney, L, Goble, S, Lin, K, Kwan, T, Ledermann, J, Coleman, R, O'Malley D. M., Oza A. M., Lorusso D., Aghajanian C., Oaknin A., Dean A., Colombo N., Weberpals J. I., Clamp A. R., Scambia G., Leary A., Holloway R. W., Gancedo M. A., Fong P. C., Goh J. C., Swisher E. M., Maloney L., Goble S., Lin K. K., Kwan T., Ledermann J. A., Coleman R. L., O'Malley, D, Oza, A, Lorusso, D, Aghajanian, C, Oaknin, A, Dean, A, Colombo, N, Weberpals, J, Clamp, A, Scambia, G, Leary, A, Holloway, R, Gancedo, M, Fong, P, Goh, J, Swisher, E, Maloney, L, Goble, S, Lin, K, Kwan, T, Ledermann, J, Coleman, R, O'Malley D. M., Oza A. M., Lorusso D., Aghajanian C., Oaknin A., Dean A., Colombo N., Weberpals J. I., Clamp A. R., Scambia G., Leary A., Holloway R. W., Gancedo M. A., Fong P. C., Goh J. C., Swisher E. M., Maloney L., Goble S., Lin K. K., Kwan T., Ledermann J. A., and Coleman R. L.
- Abstract
Objective: ARIEL3 (NCT01968213) is a placebo-controlled randomized trial of the poly(ADP-ribose) polymerase inhibitor rucaparib as maintenance treatment in patients with recurrent high-grade ovarian carcinoma who responded to their latest line of platinum therapy. Rucaparib improved progression-free survival across all predefined subgroups. Here, we present an exploratory analysis of clinical and molecular characteristics associated with exceptional benefit from rucaparib. Methods: Patients were randomized 2:1 to receive rucaparib 600 mg twice daily or placebo. Molecular features (genomic alterations, BRCA1 promoter methylation) and baseline clinical characteristics were evaluated for association with exceptional benefit (progression-free survival ≥2 years) versus progression on first scan (short-term subgroup) and other efficacy outcomes. Results: Rucaparib treatment was significantly associated with exceptional benefit compared with placebo: 79/375 (21.1%) vs 4/189 (2.1%), respectively (p < 0.0001). Exceptional benefit was more frequent among patients with favorable baseline clinical characteristics and with carcinomas harboring molecular evidence of homologous recombination deficiency (HRD). A comparison between patients who derived exceptional benefit from rucaparib and those in the short-term subgroup revealed both clinical markers (no measurable disease at baseline, complete response to latest platinum, longer penultimate platinum-free interval) and molecular markers (BRCA1, BRCA2, RAD51C, and RAD51D alterations and genome-wide loss of heterozygosity) significantly associated with exceptional benefit. Conclusions: Exceptional benefit in ARIEL3 was more common in, but not exclusive to, patients with favorable clinical characteristics or molecular features associated with HRD. Our results suggest that rucaparib can deliver exceptional benefit to a diverse set of patients with recurrent high-grade ovarian carcinoma.
- Published
- 2022
49. Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
- Author
-
Lorusso, D, Danesi, R, Locati, L, Masi, G, De Giorgi, U, Gadducci, A, Pignata, S, Roberto, S, Savarese, A, Valabrega, G, Zamagni, C, Colombo, N, Lorusso D., Danesi R., Locati L. D., Masi G., De Giorgi U., Gadducci A., Pignata S., Roberto S., Savarese A., Valabrega G., Zamagni C., Colombo N., Lorusso, D, Danesi, R, Locati, L, Masi, G, De Giorgi, U, Gadducci, A, Pignata, S, Roberto, S, Savarese, A, Valabrega, G, Zamagni, C, Colombo, N, Lorusso D., Danesi R., Locati L. D., Masi G., De Giorgi U., Gadducci A., Pignata S., Roberto S., Savarese A., Valabrega G., Zamagni C., and Colombo N.
- Abstract
Introduction: The combination of lenvatinib plus pembrolizumab demonstrated a relevant clinical benefit in patients with endometrial carcinoma. The safety profile was consistent with the established profiles of each drug in monotherapy, with the most frequent adverse events being hypertension, an on-target effect, hypothyroidism, diarrhea, nausea, vomiting, loss of appetite, fatigue, and weight loss. Areas covered: We first review the rationale based on the combination of a VEGFR inhibitor and an immune checkpoint inhibitor, highlighting the main pharmacokinetic and pharmacodynamic features of lenvatinib. Next, we focus on the common adverse events associated with lenvatinib and guide how to optimally prevent, detect, and manage them, while minimizing interruptions during lenvatinib treatment. Discussion: The side effects profile of lenvatinib is very well known, being similar across different tumor types. Most toxicities can be preventable. An appropriate, proactive, and thorough management of lenvatinib toxicities during treatment is required to maximize potential lenvatinib efficacy. Adverse events should be detected as early as possible, by both carefully monitoring the patient from lenvatinib initiation and preventing their occurrence. Patients should be followed also during treatment as some adverse events, e.g., cardiac dysfunction might appear later. Increased awareness on risk to benefit ratio among clinicians would be helpful to avoid dose interruptions or discontinuation of lenvatinib, with preferring other medical interventions and supportive care.
- Published
- 2022
50. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies
- Author
-
Russo, A, Incorvaia, L, Capoluongo, E, Tagliaferri, P, Gori, S, Cortesi, L, Genuardi, M, Turchetti, D, De Giorgi, U, Di Maio, M, Barberis, M, Dessena, M, Del Re, M, Lapini, A, Luchini, C, Jereczek-Fossa, B, Sapino, A, Cinieri, S, Beretta, G, Bella, M, Bracarda, S, Colombo, N, Conteduca, V, Del Mastro, L, Galvano, A, Gristina, V, Guarneri, V, La Verde, N, Lorusso, D, Marchetti, P, Normanno, N, Ottini, L, Pensabene, M, Pignata, S, Procopio, G, Ricevuto, E, Silvestris, N, Tassone, P, Tucci, M, Donato, V, Carrara, S, Paiella, S, Gentilini, O, Gunelli, R, Nicolis, F, Buttitta, F, Colecchia, M, Fassan, M, Malapelle, U, Marchetti, A, Marchio, C, Scarpa, A, Truini, M, Zamboni, G, Gion, M, Trevisiol, C, Gronchi, A, Danesi, R, Di Marco, V, Carrera, P, Ghiorzo, P, Pasini, B, Varesco, L, Artibani, W, Ludovico, G, Campanella, O, Vatrano, S, Tagliafico, E, Russo A., Incorvaia L., Capoluongo E., Tagliaferri P., Gori S., Cortesi L., Genuardi M., Turchetti D., De Giorgi U., Di Maio M., Barberis M., Dessena M., Del Re M., Lapini A., Luchini C., Jereczek-Fossa B. A., Sapino A., Cinieri S., Beretta G., Bella M. A., Bracarda S., Colombo N., Conteduca V., Del Mastro L., Galvano A., Gristina V., Guarneri V., La Verde N., Lorusso D., Marchetti P., Normanno N., Ottini L., Pensabene M., Pignata S., Procopio G., Ricevuto E., Silvestris N., Tassone P., Tucci M., Donato V., Carrara S., Paiella S., Gentilini O., Gunelli R., Nicolis F., Buttitta F., Colecchia M., Fassan M., Malapelle U., Marchetti A., Marchio C., Scarpa A., Truini M., Zamboni G., Gion M., Trevisiol C., Gronchi A., Danesi R., Di Marco V., Carrera P., Ghiorzo P., Pasini B., Varesco L., Artibani W., Ludovico G., Campanella O., Vatrano S., Tagliafico E., Russo, A, Incorvaia, L, Capoluongo, E, Tagliaferri, P, Gori, S, Cortesi, L, Genuardi, M, Turchetti, D, De Giorgi, U, Di Maio, M, Barberis, M, Dessena, M, Del Re, M, Lapini, A, Luchini, C, Jereczek-Fossa, B, Sapino, A, Cinieri, S, Beretta, G, Bella, M, Bracarda, S, Colombo, N, Conteduca, V, Del Mastro, L, Galvano, A, Gristina, V, Guarneri, V, La Verde, N, Lorusso, D, Marchetti, P, Normanno, N, Ottini, L, Pensabene, M, Pignata, S, Procopio, G, Ricevuto, E, Silvestris, N, Tassone, P, Tucci, M, Donato, V, Carrara, S, Paiella, S, Gentilini, O, Gunelli, R, Nicolis, F, Buttitta, F, Colecchia, M, Fassan, M, Malapelle, U, Marchetti, A, Marchio, C, Scarpa, A, Truini, M, Zamboni, G, Gion, M, Trevisiol, C, Gronchi, A, Danesi, R, Di Marco, V, Carrera, P, Ghiorzo, P, Pasini, B, Varesco, L, Artibani, W, Ludovico, G, Campanella, O, Vatrano, S, Tagliafico, E, Russo A., Incorvaia L., Capoluongo E., Tagliaferri P., Gori S., Cortesi L., Genuardi M., Turchetti D., De Giorgi U., Di Maio M., Barberis M., Dessena M., Del Re M., Lapini A., Luchini C., Jereczek-Fossa B. A., Sapino A., Cinieri S., Beretta G., Bella M. A., Bracarda S., Colombo N., Conteduca V., Del Mastro L., Galvano A., Gristina V., Guarneri V., La Verde N., Lorusso D., Marchetti P., Normanno N., Ottini L., Pensabene M., Pignata S., Procopio G., Ricevuto E., Silvestris N., Tassone P., Tucci M., Donato V., Carrara S., Paiella S., Gentilini O., Gunelli R., Nicolis F., Buttitta F., Colecchia M., Fassan M., Malapelle U., Marchetti A., Marchio C., Scarpa A., Truini M., Zamboni G., Gion M., Trevisiol C., Gronchi A., Danesi R., Di Marco V., Carrera P., Ghiorzo P., Pasini B., Varesco L., Artibani W., Ludovico G., Campanella O., Vatrano S., and Tagliafico E.
- Abstract
Constitutional BRCA1/BRCA2 pathogenic or likely pathogenic variants (PVs) are associated with an increased risk for developing breast and ovarian cancers. Current evidence indicates that BRCA1/2 PVs are also associated with pancreatic cancer, and that BRCA2 PVs are associated with prostate cancer risk. The identification of carriers of constitutional PVs in the BRCA1/2 genes allows the implementation of individual and family prevention pathways, through validated screening programs and risk-reducing strategies. According to the relevant and increasing therapeutic predictive implications, the inclusion of BRCA testing in the routine management of patients with breast, ovarian, pancreatic and prostate cancers represent a key requirement to optimize medical or surgical therapeutic and prevention decision-making, and access to specific anticancer therapies. Therefore, accurate patient selection, the use of standardized and harmonized procedures, and adherence to homogeneous testing criteria, are essential elements to implement BRCA testing in clinical practice. This consensus position paper has been developed and approved by a multidisciplinary Expert Panel of 64 professionals on behalf of the AIOM–AIRO–AISP–ANISC–AURO–Fondazione AIOM–SIAPEC/IAP–SIBioC–SICO–SIF–SIGE–SIGU–SIU–SIURO–UROP Italian Scientific Societies, and a patient association (aBRCAdaBRA Onlus). The working group included medical, surgical and radiation oncologists, medical and molecular geneticists, clinical molecular biologists, surgical and molecular pathologists, organ specialists such as gynecologists, gastroenterologists and urologists, and pharmacologists. The manuscript is based on the expert consensus and reports the best available evidence, according to the current eligibility criteria for BRCA testing and counseling, it also harmonizes with current Italian National Guidelines and Clinical Recommendations.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.